The Effects of Vaping and Smoking on Respiratory

Function and Inflammation; Can they be Reversed by

Aerobic Exercise and Vaping and Smoking Cessation? by Darabseh, Mohammad Zaid
1 | P a g e  
 
 
The Effects of Vaping and Smoking on Respiratory 
Function and Inflammation; Can they be Reversed by 




Mohammad Z. Darabseh 
 
PhD 2021
2 | P a g e  
 
 
The Effects of Vaping and Smoking on Respiratory Function and 
Inflammation; Can they be Reversed by Aerobic Exercise and 
Vaping and Smoking Cessation? 
 
Mohammad Zaid Darabseh 
 
A thesis submitted in partial fulfilment of the requirements of 
Manchester Metropolitan University for the degree of Doctor of 
Philosophy 
 
Manchester Metropolitan University 
Department of Life Sciences 
School of Healthcare Science 
May 2021
3 | P a g e  
 
Acknowledgment  
To begin with, my utmost appreciation goes to my amazing supervisory team, Prof Hans 
Degens (director of studies), Prof James Selfe (first supervisor) and Dr Chris Morse 
(second supervisor), as they were representing the standards of professional excellence, 
to which I really aspire. Thank you all for the tireless advice and support throughout the 
PhD journey. Thank you all for providing me with encouragement when needed, and 
constructive feedback to enhance the quality of my work and always making things 
happen. Hans, thanks for always being there, I will never forget your prompt responses 
and our evening meetings.  
 
To me, despite of all the difficulties I have faced, and indeed did overcome, it was the 
journey of learning, patience, passion, gaining knowledge and new skills, achievement, 
chasing my dreams, improving the critical thinking and ultimately, SUCCESS! and as Hans 
said once, ‘’we are getting there on all fronts, of which I am very pleased! We are winning 
the battle(s)!’’ 
I would like to acknowledge and thank all the lab technicians who helped during 
conducting the lab experiments. Also, the students who I supervised and all the 
participants who took part in the project. 
 
I dedicate this work to my parents, Elham Qerba’a and Zaid Darabseh who made the 
impossible, possible for me. Whenever I thought about giving up, I remembered them, in 
which only thinking how they will be proud of me, imagining the happiness in their eyes, 
made me keep it up and push harder. I always remembered my family, my soulmates and 
brothers Eyad and Gaith and their families. My beautiful caring sisters, Shaima’a and 
Baida’a, thank you all for the love, care, support and prayers. I won’t forget my father and 
mum in law, thanks as always being there for us. 
 
It has always been said that the PhD is like a Rollercoaster: ups and downs. Aseel- my 
friend, my wife and my soulmate- was always cheering me and bringing me up. Despite 
her own PhD stuff, and even bringing to us a little angel - little Zaid, even during that 
4 | P a g e  
 
tough time, she was amazing in supporting me and made everything possible for me. 
Thank you for bearing with me, for the tireless nights, you never left my side over the 
years and through every step of this journey. The successful completion of this work 
would have been impossible without your support, love and encouragement, my Babel 
Rose! I will always remember Aseels’ words ‘‘things that passes, finishes!’’ 
 
Aseel and Zaid, we finally made it! I want our little one-Zaid- to learn not to give up, I 
want him to learn that we have to try hard to achieve our goals. 
 
 
5 | P a g e  
 
Abstract 
Introduction: Vaping is marketed as a healthier alternative to smoking, but little is known 
about the effects of vaping on cardiorespiratory function. Smoking cessation (SC) is a 
strategy to stop and/or reverse the detrimental effects of smoking, and one of the 
techniques used to encourage smokers quit is aerobic exercise. The aim of this thesis was 
to assess the effects of vaping and smoking on respiratory and muscle function, and 
systemic inflammation, and whether effects can be reversed by SC with or without 
aerobic exercise. Specific objectives are: To 1) compare the respiratory function and 
respiratory muscle strength between vapers, smokers and non-smokers; 2) assess the 
effects of 14 days SC on respiratory and muscle function and low-grade systemic 
inflammation; and 3) determine the effects of aerobic exercise on vaping and smoking 
cessation. Methods: 1) In 12 vapers, 14 smokers and 18 non-smokers spirometry and 
respiratory muscle strength were measured; 2) in 48 cigarette smokers the impact of 14 
days SC on spirometry, skeletal muscle function, markers of oxidative stress and serum 
cytokines were determined and 3) in a systematic review with meta-analysis the effects of 
aerobic exercise on vaping and SC and maximal or peak oxygen uptake were determined. 
Results: 1) Both vapers and smokers had a similarly lower respiratory function than non-
smokers, but there was no evidence for a lower respiratory muscle strength. 2) Smoking 
cessation did not reverse the lower respiratory function, but it did reverse the low-grade 
systemic inflammation and impaired muscle function. 3) Aerobic exercise did not 
significantly increase the success rate of quitting, but it did improve cardiopulmonary 
fitness. Conclusion: Vaping causes similar detrimental effects as smoking on lung 
function. As little as 14 days of SC reversed the low-grade systemic inflammation and 
impaired muscle function in smokers. Aerobic exercise added to a SC programme did not 
increase the success rate of quitting, but it did improve the fitness of the quitters. 
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Chapter 1 : General Introduction  
 
 
Part of this chapter has been published as 
Darabseh, M.Z., Selfe, J., Morse, C.I. and Degens, H., 2020. Is vaping better than 
smoking for cardiorespiratory and muscle function? Multidisciplinary respiratory 
medicine, 15(1). 
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1.1. Background 
Cigarette packages contain warning labels like ‘Smoking Kills’ and ‘Smoking clogs the 
arteries and causes heart attacks and stroke’. These labels illustrate the tragic truth that 
smoking is a major risk factor for the development of cancer, cardiovascular diseases 
(CVD) and respiratory disorders including chronic obstructive pulmonary disease (COPD). 
In addition, smoking causes systematic inflammation, as reflected by an increase in white 
blood cells (WBC) count and inflammatory cytokines (Abdul-Rasheed and Al-Rubayee, 
2013; Aula and Qadir, 2013; Bloomer, 2007; Morrow et al., 1995). It causes more than 7 
million deaths per year globally (World Health Organization, 2017) and in 2016, 77,900 
deaths in the United Kingdom (UK) were directly or indirectly attributable to smoking 
(Office for National Statistics, 2017). Yet, these labels do not appear enough of a 
deterrent as about 7.2 million of the UK population are smokers (Office for National 
Statistics, 2019).  
These disastrous effects of smoking develop unperceivably slowly and only later in life, 
the detrimental health issues become evident (Lopez et al., 1994), a phenomenon 
referred to as ‘the smoking time-bomb’. To make matters worse, ‘The beneficial cognitive 
effects of nicotine have implications for initiation of smoking and maintenance of tobacco 
dependence’ (Heishman et al., 2010). 
Any means to administer nicotine, but without the concomitant inhalation of the more 
than 4,000 toxic substances in cigarette smoke, such as acrolein, carbon monoxide (CO), 
acetaldehyde and cyanide, would thus be preferable to cigarette smoking. E-cigarettes 
containing nicotine are considered to do this. The success of e-cigarettes in reducing 
smoking is reflected by the fact that about 54.1% of the current 3.6 million adult e-
cigarette users in the UK are ex-smokers  (Action on Smoking and Health, 2019). 
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There is, however, concern that e-cigarettes may singularly stimulate uptake of smoking, 
particularly in youth, and have an acute effect on cardiorespiratory health, even in the 
absence of smoking (Korfei, 2018; Schraufnagel et al., 2014). Additionally, there are 
potential risks with vaping during pregnancy and lactation on the development of the 
child in the womb and health of the new born baby (Kuehn, 2019; McAlinden et al., 2017; 
Orzabal et al., 2019). Indeed, vapours from e-cigarettes contain, besides nicotine and the 
respiratory irritant propylene glycol, toxic substances also seen in cigarette smoke, such 
as acrolein, acetaldehyde, formaldehyde and reactive oxygen species. As seen in animal 
studies, these toxic substances may well cause oxidative stress and negative effects on 
cardiovascular and respiratory function after vaping (Korfei, 2018), casting doubt on the 
idea that e-cigarettes are a suitable ‘healthy’ alternative to normal cigarettes. Yet, there 
are only basic regulations for the composition of e-cigarette liquids (as described in 
https://www.gov.uk/guidance/e-cigarettes-regulations-for-consumer-products). 
The potential health risk of e-cigarettes led the Forum of International Respiratory 
Societies to release a position statement that concluded: ‘As a precaution, electronic 
nicotinic delivery devices should be restricted or banned until more information about 
their safety is available’ (Schraufnagel et al., 2014). There is, thus an unmet need to know 
the effects of vaping on respiratory function in humans, and how this is related to the 
daily vaping volume and/or for how long one has been vaping.  
1.2. The dangers of nicotine in e-cigarettes 
An e-cigarette is composed of a rechargeable lithium battery, vaporizing chamber and a 
cartridge that contains the vaping liquid that consists, among other substances, of 
nicotine, glycerol, propylene glycol, glycerine and tobacco flavouring (Cobb and Abrams, 
2011; Westenberger, 2009), although some vaping liquids may be free of nicotine. 
Nicotine is easily absorbed by the mucus membrane, skin, gastrointestinal tract and 
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respiratory airways (Callahan-Lyon, 2014) and acts as a neurotransmitter that in turn 
stimulates the release of dopamine, which contributes to the feeling of pleasure and 
satisfaction as part of the reward pathway (Bressan and Crippa, 2005). It is this effect of 
nicotine that makes smoking so addictive (Benowitz, 2010). As mentioned above, the 
dose of nicotine in e-cigarettes can be very high; typically, a 5-mL bottle of e-cigarette 
refill solution consist of 20 mg/ml nicotine (that is 100 mg/bottle) (Cameron et al., 2014). 
The life threatening dose of nicotine is around 30 to 40 mg in adults and 10 mg in children 
(Cameron et al., 2014). This high dose combined with unlimited vaping poses a potential 
health risk as it has been shown that acute contact to high concentrations of inhaled 
nicotine, or even skin contact e.g. after spills of nicotine-containing solutions, may cause 
nausea, vomiting or dizziness (Callahan-Lyon, 2014; Ordonez et al., 2013). Such risks are 
even higher in vaping than in smoking, where such poisonous nicotine levels rarely occur 
(Centers for Disease Control Prevention, 1997). In fact, many successful and unsuccessful 
suicide attempts through intravenous and oral intake of the nicotine solution intended for 
e-cigarette cartridges have been reported (Christensen et al., 2013; Thornton et al., 2013; 
Valento, 2013).  
1.3. Chemical components of e-cigarettes   
Besides nicotine there are other chemicals in the vaping liquids, where propylene glycol 
constitutes 90% of the e-cigarette liquid (Laugesen, 2008). While propylene glycol is often 
used to produce the smoke in special events like rock concerts and is considered 
harmless, prolonged and repeated exposure to propylene glycol vapour has been 
reported to cause cough, irritations of the eyes and lungs (Wieslander et al., 2001), and to 
increase the risk of acquiring asthma (Choi et al., 2010). Vaping liquid also contains 1% 
diethylene glycol, a known carcinogen (Goniewicz et al., 2014; Westenberger, 2009), 
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when non-pharmaceutical grade propylene glycol is used (Cahn and Siegel, 2011). While 
many of the flavours in e-liquids are safe when ingested and widely used in the food 
industry. The potential dangers of inhaling flavours are not yet fully investigated, but 
there are indications they may have a negative effect on lung health. For example, 
diacetyl is used in butter and safe when ingested, but when heated and inhaled it might 
cause bronchiolitis (Harber et al., 2006). In addition, some studies have shown that e-
cigarettes release aromatic, particularly the carcinogenic component, polycyclic aromatic 
hydrocarbons, that have a pathogenic effect on human lung cells (Rankin et al., 2019), 
and contain esters, aldehydes, acids or saccharides that are cariogenic (Kim et al., 2018). 
In addition to these compounds, there are many more carcinogenic compounds in e-
cigarette liquids (Goniewicz et al., 2014; Talhout et al., 2011), particularly trace metals 
(i.e., cadmium, arsenic, chromium, nickel, and lead), and tobacco-specific N-nitrosamines, 
and all these substances can in some cases reach concentrations even higher than in 
cigarette smoke (Williams et al., 2013). Perhaps most surprising, given that smoking is a 
primary risk factor for pulmonary diseases, is that the most common used e-cigarette 
refill liquids are classified as respiratory irritants, allergens, inducers of asthmatic 
symptoms or potentially causing breathing difficulties if inhaled (Vardavas et al., 2017).  
There is as yet no strong evidence that passive exposure to vaping has adverse effects on 
health. However, the detrimental effects of passive smoking and the observation that 
nicotine released into the environment does not only affect those who inhale it, but may 
also affect non-smokers and non-vapers via nicotine left on surfaces e.g. furniture, 
carpets and clothes (Matt et al., 2020), strongly hints to the dangers of passive exposure 
to the e-cigarette aerosols.  
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1.4. Effects of cigarette smoking on cardiovascular function 
It is known that cigarette smoking reduces the cardiopulmonary fitness, as reflected by a 
reduced maximum oxygen consumption (VO2max) (de Borba et al., 2014; Lauria et al., 
2017).  The lower exercise capacity in smokers is, however, not only attributable to a 
reduction in aerobic capacity, but also an increased metabolic cost of breathing (de Borba 
et al., 2014; Lauria et al., 2017; Misigoj-Durakovic et al., 2012). 
Smoking increases blood pressure (BP), resting HR, the risk factor for atherosclerosis 
(Campisi et al., 1998; Groppelli et al., 1992) and has been shown to impair cardiovascular 
function, increase vascular resistance, and decrease vasodilation and hence tissue blood 
flow (Campisi et al., 1998). The impaired vasodilation (Celermajer et al., 1992) can even 
occur after short-term smoking (Lekakis et al., 1997). Such an effect is not limited to the 
peripheral vasculature. Indeed, a narrowing of the coronary arteries, and hence decrease 
in coronary blood flow and increase coronary resistance, despite an increase in 
myocardial oxygen demand, has been reported as a result of acute cigarette smoking 
(Quillen et al., 1993). The authors suggested that such ongoing effects with prolonged 
smoking may well contribute to the adverse cardiovascular consequences of cigarette 
smoking, such as myocardial infarction and cardiac failure (Quillen et al., 1993).  
1.5. Effects of cigarette smoking on muscle size and function 
Many studies have described the negative effects of smoking on skeletal muscle function 
and morphology, specifically, the thigh muscles (Larsson and Örlander, 1984). One aspect 
is decreased muscle fatigue resistance (Wüst et al., 2008c) associated with  reduced 
muscle oxidative capacity (Degens and Veerkamp, 1994) and a slow twitch to fast twitch 
fibre type transition (Örlander et al., 1979). A diminished oxygen delivery due to the 
interaction of CO with haemoglobin may hamper the mitochondria to resynthesize 
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Adenosine triphosphate (ATP). The ability of the mitochondria to synthesise ATP can be 
further aggravated by mitochondrial dysfunction due to interaction of CO and other 
substances in cigarette smoke with elements of oxidative phosphorylation, and combined 
with the other changes already discussed, cause a reduction in muscle contractile 
endurance (Degens et al., 2015). Furthermore, smoking could promote skeletal muscle 
wasting via smoking-induced inflammation that increases protein breakdown and 
decreases protein synthesis (Degens et al., 2015; Petersen et al., 2007) and results in a 
reduced maximal force-generating capacity of the muscles from smokers (Barreiro et al., 
2010; Seymour et al., 2010). Figure 1.1 shows the mechanism whereby smoking may have 
a negative impact on muscle function, such as that caused by reactive oxygen species and 
free radicals and impaired oxygen delivery due to carbon monoxide in cigarette smoke.   
 
Figure 1.1: Mechanisms whereby smoking may affect skeletal muscle mass and function. 
ERK = extracellular signal–regulated kinase; MAFBx = muscle atrophy F-box; MAPK = mitogen-
activated protein kinase; MuRF1 = muscle ring finger-1; NF-κB = nuclear factor-κB; ROS =  reactive 
oxygen species; TNF-α = tumor necrosis factor-α. Figure and caption were taken from (Degens et 
al., 2015). 
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1.6. Effects of vaping and smoking on respiratory function 
Cigarette smoke irritates the lining of the bronchial tubes causing them to swell and 
produce mucus to remove smoke particles (Hogg et al., 2004). Emphysema may develop 
when smoke particles irritate the alveolar walls and inflammation stimulates the release 
of proteases, enzymes that leads to the destruction of elastic fibres and collagen, which 
subsequently culminate in the destruction of the alveolar walls (Centers for Disease 
Control Prevention, 2010; Hogg et al., 2004). Over time, this can lead to a decreased 
elastic recoil of the lung, chronic bronchitis and narrowing of the bronchial tubes that 
increases the resistance, and hence, cost of breathing (Hogg et al., 2004; Stănescu et al., 
1996). Ultimately, this progressive decrease in lung function can develop into COPD (Wüst 
and Degens, 2007) that is diagnosed in 6.6% of the United states (US) population, of 
which 75% are smokers (Salvi and Barnes, 2009; Wheaton et al., 2019). Additionally, the 
respiratory muscle strength, as measured by maximal inspiratory and expiratory mouth 
pressures, was reduced in healthy smokers (Bostanci et al., 2019). 
In contrast to smoking, the effects of vaping on human health and respiratory function 
are poorly investigated (Palazzolo, 2013), but it has been shown that vaping for just 5 min 
increased peripheral airway resistance (Vardavas et al., 2012). This is, however, not 
unequivocal, as another study found no acute effects of active vaping on lung function  
(Flouris et al., 2013). Whatever the cause of the discrepancy, it has been suggested that 
the increased peripheral airway resistance after 5 min of vaping (Vardavas et al., 2012) is 
partially caused by nicotine (Palazzolo, 2013). Indeed, nicotine inhalation (0-64 mg/ml) 
showed a dose-dependent increase in the amount of coughing and airway obstruction in 
non-smokers, which may be a consequence of the stimulation of afferent nerve endings 
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in the bronchial mucosa by nicotine, which in turn triggers parasympathetic cholinergic 
pathways leading to bronchoconstriction (Hansson et al., 1994). Nicotine is, however, not 
the whole explanation, as respiratory symptoms, and airway inflammation were even 
found in vapers who used nicotine-free e-cigarettes (Vakali et al., 2013).  
Over time, the above effects of vaping may cause acute small-airway constriction and 
airway epithelial injury (Chaumont et al., 2018) that may be linked to increased risk of 
wheezing and respiratory symptoms similar to those seen in cigarette smokers (Li et al., 
2019). McCauley et al. (2012) presented a case study of a 42-year-old woman diagnosed 
with exogenous lipoid pneumonia due to vaping. She had a history of 7-months 
productive cough, fevers and dyspnoea which occurred at the same time of her use of e-
cigarettes (McCauley et al., 2012). Glycerine, which is a component added to e-cigarette 
liquid to produce visible smoke to simulate the cigarette smoking experience, was found 
to be the causative agent, and symptoms improved by vaping cessation (quit vaping) 
(McCauley et al., 2012). The above example may be considered anecdotal, but in a study 
of 30 vapers who never smoked, it was seen that the Forced Expiratory Volume in one 
second (FEV1) and Forced Expiratory Volume in one second/Forced Vital Capacity 
(FEV1/FVC) were significantly lower than those in controls (non-vapers and non-smokers) 
(Meo et al., 2019), similar to that seen in smokers (Kiter et al., 2000; Sparrow et al., 1983) 
(Figure 1.2).  
In contrast to the above cross-sectional study where vapers and non-vapers were 
compared (Meo et al., 2019), in a 3.5-year prospective study no significant decrements in 
spirometry or diffusion capacity were found in vapers (Polosa et al., 2017). Perhaps 
studies with a larger sample size are needed, as there are studies that have also not seen 
any significant effect of smoking on respiratory function (Wüst et al., 2008c). Overall, 
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Figure 1.2: The effect of vaping on A) forced expiratory volume in one second (FEV1) and B) FEV1:FVC 
(forced vital capacity). Data are mean ± SD. * different from controls at p<0.05. Data are from (Meo 
et al., 2019), and (Sparrow et al., 1983). To make the data between the two studies comparable, in 
each study the data were normalised to the control group. 
combined with the detrimental impact of vaping on the lungs of mice (Glynos et al., 2018) 
the data suggest that vaping has a detrimental effect on lung function. 
 
1.7. Effects of smoking on exercise 
Smoking can cause acute and long-lasting impairments in endurance and exercise 
capacity, and increase the rates of injury and development of chronic diseases (Elbehairy 
et al., 2016; Mendonca et al., 2011). One of the causes of a reduced exercise capacity is 
carbon monoxide in cigarette smoke that via binding to haemoglobin impairs the oxygen 
delivery to the working muscles (Guyton and Hall, 2006). As a consequence, the ATP 
required for muscle contraction will be derived more than in non-smokers from glycolysis, 
resulting in an earlier and faster accumulation of lactic acid (the substance that causes 
muscle “burning,” fatigue, heavier breathing, and increased soreness after exercise) and 
hence a reduction in the pH of the muscle fibres that hampers muscle contraction 
(Guyton and Hall, 2006). This section summarises briefly in somewhat more detail the 
main effects of smoking not only on skeletal muscle, but also the heart and the 
respiratory system, and the consequences for exercise capacity in smokers. 
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One of the almost immediate effects of smoking is the binding of carbon monoxide to 
haemoglobin that can significantly impair the oxygen carrying capacity of the blood and at 
the same time impedes the release of the oxygen that is bound to haemoglobin, reflected 
by a left-shift of the haemoglobin dissociation curve (Degens et al., 2015). Therefore, for 
the same oxygen consumption, the cardiac output is elevated after smoking just one 
cigarette in smokers (Hirsch et al., 1985). This thus increases the work of the heart, 
further compounded by the increase in heart rate induced by the nicotine-induced 
release of adrenaline. In fact, the effect of nicotine is even evident at rest, where just 
within the first ten minute of smoking, heart rate increased by up to 30% (Hayano et al., 
1990). One of the more serious longer term effects of smoking is atherosclerosis (Howard 
et al., 1998), which via a reduction of the diameter of arteries  can lead to a lower 
perfusion of muscles during exercise, and in the heart can result in coronary heart 
disease, characterised by diminished perfusion to the heart muscle (Critchley and 
Capewell, 2003).  
Besides the effects of smoking on the heart and skeletal muscle, it is also known to cause 
dyspnoea during exercise, even in healthy smokers (Wang et al., 1995). This problem may 
derive from reductions in lung volumes and respiratory muscle weakness, and further 
contribute to reduced exercise capacity and endurance in healthy smokers (Elbehairy et 
al., 2016; Wang et al., 1995).  
In addition to the cardiac and pulmonary complication, particularly endurance capacity 
may be diminished also due to a lower proportion of highly oxidative type I fibres (Ide and 
Tabira, 2013), further compounded by muscle fibre atrophy. Figure 1.3 is a schematic 
summary for the main effects of smoking on the cardiovascular, respiratory and 
musculoskeletal systems that might lead to exercise intolerance.  
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Perhaps somewhat unexpected is the potential detrimental impact of smoking on bone 
mineral density (Wust et al., 2010) that may lead to an earlier onset of osteoporosis (Krall 
and Dawson‐Hughes, 1999). Part of this reduction in bone mineral density may be 
attributable to a 20mg/day lower calcium availability in smoker than non-smokers, 
resulting from a impaired ability to absorb calcium (Krall and Dawson‐Hughes, 1999). 
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Figure 1.3: Schematic summary for the main effects of smoking on the cardiovascular, respiratory and musculoskeletal systems that 
might lead to exercise intolerance. 
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1.8. Effects of smoking on haematology parameters and oxidative stress 
biomarkers 
The harmful compounds in cigarette smoke may increase the risk of CVD by increasing the 
production of free radicals, oxidative stress and low-grade systemic inflammation even 
otherwise in healthy smokers (Abdul-Rasheed and Al-Rubayee, 2013; Bloomer, 2007; 
Lykkesfeldt et al., 2004; Morrow et al., 1995). The low-grade systemic inflammation is 
reflected by increased numbers of circulating WBC and elevated levels of inflammatory 
cytokines, such as interleukin-1 (IL-1), Interleukin-6 (IL-6), and tumour necrosis factor α 
(TNF-α) (Aula and Qadir, 2013). In addition to systemic inflammation, smoking is 
associated with elevated serum cholesterol and triglyceride levels, impaired glucose 
tolerance and reduced insulin sensitivity (Frati et al., 1996). It has been reported that in 
diabetic people, a reduced insulin sensitivity could lead to glycation of myofibrillar 
proteins (Syrový and Hodný, 1992) that may be further aggravated by glycotoxins in 
cigarette smoke that can also react with serum proteins to form advanced glycation end 
products (AGEs) (Cerami et al., 1997).  
1.9. Vaping cessation and smoking cessation  
Since 1963 cigarette companies have been working to invent a new smoking system such 
as electronic nicotine delivery systems (ENDS) that heats, instead of burns, tobacco to 
reduce harm, and presents as a socially acceptable alternative to smoking (Glantz and 
Forbes, 1996; Ling and Glantz, 2005). The credit of inventing the e-cigarette as an 
alternative to smoking goes to Hon Lik, a Chinese pharmacist and inventor, whose heavy-
smoking father died from lung cancer (Demick, 2009; Lik, 2004). Many companies 
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worldwide have adopted this technology and started marketing e-cigarettes as a harmless 
and safe alternative to cigarette smoking (Dutra et al., 2017).  
Smoking cessation is a vital strategy to slow or reverse many of the harmful effects of 
smoking. It is efficient to slow down the accelerated decline in FEV1 (Anthonisen, 1997; 
Kanner et al., 1999) and it reduces morbidity and mortality (Rodrigues et al., 2014). In 
fact, it was reported that smoking-induced lung inflammation, mitochondrial dysfunction, 
limb muscle and diaphragm muscle atrophy were reversed after two weeks smoking 
cessation in  mice (Ajime et al., 2021). Additionally, smoking cessation normalised the 
elevated IL-1α and TNF-α levels induced by smoking (Ajime et al., 2021; Braber et al., 
2010). In addition, smoking cessation might result in a quick normalisation of 
carboxyhaemoglobin to levels seen in non-smokers, which might be associated with an 
improvement in exercise tolerance and skeletal muscle fatigue resistance (Kambam et al., 
1986). 
As the cardiorespiratory system is the most affected organ system by smoking, smoking 
cessation is of benefit to stop and/or reverse its detrimental effects. Indeed, smoking 
cessation has been reported to alleviate at least some of the CVD conditions as indicated 
by improvement in treadmill stress testing (Asthana et al., 2012). So, in addition to vaping 
as a tool to facilitate smoking cessation, more tools and strategies are needed to help 
smokers quit, including exercise that may even help in vaping cessation (quit vaping). 
Even if exercise does not result in enhanced smoking and/or vaping cessation, there may 
still be benefits, such as an aerobic exercise-induced increase in VO2max and increased 
lung function that are often reduced in even in healthy smokers (Bernaards et al., 2003; 
Kobayashi et al., 2004; Rawashdeh and Alnawaiseh, 2018; Wu et al., 2020). Despite these 
potential benefits, there is as yet no clear evidence about the effects of aerobic exercise 
as an intervention for vaping cessation and smoking cessation. 
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Most smokers are aware of the harmful effects of cigarette smoking. Since the 
introduction of e-cigarettes in 2003, many smokers have turned to electronic cigarettes as 
they are thought to be less harmful, instead of nicotine replacement therapy (NRT) to 
help them quit smoking (Dawkins et al., 2013; Dockrell et al., 2013; Etter, 2010; Etter and 
Bullen, 2011; Farsalinos et al., 2013; Foulds and Veldheer, 2011). In 2019, 7.1% of the 
adult population of Great Britain used e-cigarette (Action on Smoking and Health, 2019), 
and in the European Union (EU), the use of e-cigarettes increased from 7.2% in 2012 to 
11.6% in 2014 (Filippidis et al., 2017). The potential of e-cigarettes or vaping to facilitate 
smoking cessation is illustrated by the 80% decrease in the use of normal cigarettes after 
6 months of vaping (Polosa et al., 2011), and other studies showing an up to  50% 
decrease in smoked cigarettes 24 months after taking up vaping (Caponnetto et al., 2013; 
Polosa et al., 2014). In  addition, smoking cessation was reported to be as high as 8.7% 52 
weeks after taking up vaping (Caponnetto et al., 2013). In the UK, a recent trial for 
smoking cessation showed that using e-cigarette accompanied by behavioural support, 
such as face-to-face support, was more effective than NRT (Hajek et al., 2019). This is 
strong evidence that vaping indeed can reduce smoking.  
Nicotine replacement therapies expose users to low doses of nicotine (7 to 14 mg/24-
hour patch or 2 to 4 mg per piece of gum) and have been approved as medicinal products 
by the US Food and Drug Administration (FDA) (Kempton et al., 2014). E-cigarettes are 
not approved by the FDA and can be bought over the counter or online also in Europe 
(Kempton et al., 2014). The liquid in e-cigarettes have widely different nicotine 
concentrations, varying from 8 to 24 mg/ml per cartridge, but even doses up to 100 
mg/ml are readily available (Kempton et al., 2014) and pose a real risk of nicotine 
poisoning (European Commission, 2012). There is, indeed, not enough evidence that 
vaping is safe and has no, or minor, negative health effects. On the contrary, a study using 
31 | P a g e  
 
online forums reported 326 negative health-related effects of vaping, including effects on 
the respiratory, circulatory, sensory, digestive and neurological systems (Hua et al., 2013). 
1.10. Summary and conclusion 
In summary, though vaping is being marketed as safer and healthier alternative to 
smoking and therefore is promoted as a tool to help smoking cessation, there are some 
concerns that vaping may not be as healthy as generally thought (Schraufnagel et al., 
2014). Therefore, more research is required into the impact of vaping on the respiratory, 
cardiovascular and musculoskeletal system. In chapter 2 the impact of vaping or smoking 
will on the respiratory system will be evaluated and compared with that in non-smoking 
non-vaping controls. 
While smoking induces low-grade systemic inflammation and animal studies suggest that 
this can be readily reversed by smoking cessation this has not yet been studied in 
humans. In addition, little is known about the efficacy of aerobic exercise to enhance the 
success rate of smoking and/or vaping cessation and to what extent addition of aerobic 
exercise to smoking cessation programmes improves fitness. Based on these 
considerations, the objectives were to assess the effects of vaping and smoking on 
cardiorespiratory, vascular and muscle function, VO2max and low back pain. However, the 
outbreak of the Coronavirus (COVID-19) pandemic led to suspension of research activities 
as per the government guidelines. Therefore, the objectives of the study had to be re-
adjusted. The overall aim of this thesis became: to assess the effects of vaping and 
smoking on respiratory and muscle function, and inflammation and whether the effects of 
smoking can be reversed by aerobic exercise, vaping cessation and SC in healthy smokers. 
Specific objectives were: 
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• To assess respiratory function and respiratory muscle strength in vapers, 
smokers and non-smokers who are not diagnosed with airways obstruction 
(Chapter 2). Spirometry was used to assess respiratory function in chapter 2 and chapter 
3. Spirometry is considered the golden standard to assess lung function and is widely used 
to diagnose COPD (Miller et al., 2005). However, other methods that are more sensitive to 
detect changes in small airways, such as impulse oscillometry, could be used to detect 
early smoking-, or vaping-, induced decrements in pulmonary function. 
• To determine the effects of smoking cessation on respiratory function, muscle 
function, inflammation, and haematological parameters (Chapter 3). To assess 
muscle function, electrical stimulation was used to evoke repetitive isometric 
contractions to induce muscle fatigue. This test was used, and it bypasses motivational 
bias. Serum cytokines levels were quantified using flow cytometry which is a sensitive and 
widely used technique to determine the cytokines.  Serum malondialdehyde (MDA), a 
marker of lipid peroxidation, was quantified spectrophotometrically. Although there are 
more precise markers of lipid peroxidation, such as isoprostane, the technique gives a 
rough indication of levels of oxidative stress.  
• To assess the effects of aerobic exercise as an intervention on success of vaping 
cessation and smoking cessation (Chapter 4). The comprehensive search that was 
conducted and checked by two independent reviewers limited the chance of missing any 
potential articles that met the inclusion criteria. The quality of the selected papers was 
assessed by the rigorous Cochrane Risk of Bias tool 2 to exclude papers with too large a 
risk of bias. As an additional measure of quality assurance, the review protocol was 
registered in the PROSPERO database. 
The last chapter (5) of the thesis discusses the findings of the thesis.  
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Chapter 2 : Impact of Vaping and Smoking on Maximum 
Respiratory Pressures and Respiratory Function 
 
 
Part of this chapter has been published as 
Darabseh, M.Z., Selfe, J., Morse, C.I. and Degens, H., 2021. Impact of vaping and 
smoking on maximum respiratory pressures and respiratory function. International 
Journal of Adolescence and Youth, 26(1), pp.421-431.  
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2.1 Abstract: 
Objectives: It is well-known that cigarette smoking is harmful to the human body. The 
effects of electronic-cigarette use (vaping) marketed as a healthier alternative to cigarette 
smoking, on lung function in particular remain equivocal. Therefore, this study was 
conducted to assess and compare the effects of electronic cigarette use and cigarette 
smoking on maximum respiratory pressures, respiratory function and 
carboxyhaemoglobin (HbCO) levels. 
Methods: Forty-four young healthy participants were recruited: Vapers (n=12; 6 M/6 W) 
who had used e-cigarettes daily for ≥ 1year (1.67±1.00 years), Cigarette smokers (n=14; 8 
M/6 W) who had smoked daily for 4.86±2.49 years with a smoking history of 2.29±1.88 
pack years, and people who had never vaped nor smoked (control) group (n=18; 9 M/9 
W). Spirometry, maximum respiratory pressures and carboxyhaemoglobin levels were 
measured.  
Results: Men had a higher Forced expiratory volume in the first second (FEV1), Forced 
vital capacity (FVC), Peak expiratory flow (PEF), Forced expiratory flow at 25% of FVC 
(FEF25%), FEF25-75%, Maximal inspiratory pressure (MIP) and Maximal expiratory pressure 
(MEP) than woman (p<0.05). Controls had higher FEV1, PEF, FEV1/FVC, FEF25%, FEF25-75%, 
FEF25-75pred% and lower HbCO% than vapers and cigarette smokers (p<0.05). FEV1pred% was 
lower in smokers than in controls (p<0.01). Vapers and smokers did not differ significantly 
in FEV1, FEV1pred%, PEF, FEV1/FVC, FEF25%, FEF75%, FEF25-75%, FEF25-75pred% and HbCO% 
(p<0.05). Maximum respiratory pressures did not differ significantly between the three 
groups. 
Conclusion: E-cigarette use has similar detrimental effects as cigarette smoking on 
pulmonary function and may thus not be a healthier alternative to smoking.  
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2.2 Introduction 
Cigarette smoking is a well-known risk factor for the development of cancer, 
cardiovascular diseases and respiratory disorders, such as lung cancer and chronic 
obstructive pulmonary disease (COPD) (Barengo et al., 2019). Smokers are very much 
aware of these dangers and many of them seek to quit smoking. Electronic cigarettes (e-
cigarette) are marketed as a healthier alternative to cigarette smoking, as they are 
devices that do not burn tobacco, yet may deliver nicotine, and contain fewer than the 
more than 4000 toxic chemicals in cigarette smoke (Glantz and Forbes, 1996; Ling and 
Glantz, 2005; Richter et al., 2008). In the United Kingdom (UK) e-cigarettes are marketed 
as a smoke cessation product, whereas in the United States (US) they are marketed to 
young adults as an alternative for those who do not smoke (Mantey et al., 2016). The 
success of e-cigarettes to help quit smoking is reflected by the fact that 54% of e-cigarette 
users in the UK are ex-smokers (Action on Smoking and Health, 2019).  
An e-cigarette is a battery-powered device that consists of a vaporizing chamber, a 
cartridge/tank that contains the vaping liquid (e-liquid) and an atomizer that heats, rather 
than burns, the e-liquid that consists of vegetable glycerine, propylene glycol and other 
chemicals, and may contain nicotine. When the e-liquid is heated, it produces the 
aerosolized vapour that is inhaled by the vaper. Because vaping is a relatively new 
phenomenon, the impact of vaping on health has not yet thoroughly been investigated. 
However, the few studies that have investigated vaping indicate that e-cigarettes have 
detrimental effects on human health in general and on lung function in particular 
(Antoniewicz et al., 2019; Chaumont et al., 2019; Coppeta et al., 2018; Darabseh et al., 
2020; Meo et al., 2019). Interestingly, some reports found that vaping is linked with lung 
injury, named ‘E-cigarette, or vaping product use-associated lung injury’ (EVALI) including 
inducing pneumonia, hypersensitivity pneumonitis, lipoid pneumonia and diffuse alveolar 
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damage (Henry et al., 2020; Landman et al., 2019). This problem cannot be ignored, as 
reflected by the 2,807 hospitalized EVALI, mostly young adults and/or teenagers, cases or 
deaths that have been reported in the US, and the 244 suspected adverse reactions 
reported, including two fatal outcomes, in the UK (Centers for Disease Control 
Prevention, 2020; UK Medicines and Healthcare products Regulatory Agency, 2020). Thus, 
although Public Health England claimed that e-cigarettes are 95% safer than cigarette 
smoking (McNeill et al., 2015) and the prevailing idea is that vaping is not only safer, but 
also helps in smoking cessation (McNeill et al., 2015), it is far from clear that vaping is a 
healthier alternative than smoking. Therefore, the aim of this study was to compare the 
effects of vaping and smoking on lung function. It was hypothesised that vaping has a 
detrimental effect on pulmonary function, but it remains to be seen if these harmful 
effects are less, more or similar to those of cigarette smoking. In addition, there is some 
indication that smoking may impair pulmonary function in women than in men (Xu et al., 




2.3.1 Study design 
This was a laboratory-based, cross-sectional, observational study to compare pulmonary 
function in i) vapers, ii) cigarette smokers and iii) people who neither smoked nor vaped 
(controls). Ethical approval was obtained from the Science and Engineering Research 
Ethics and Governance Committee at Manchester Metropolitan University (EthOS 
reference number: 5944). All procedures adhered to the principles stated in the 
Declaration of Helsinki and all participants provided written informed consent before 
participating.  
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2.3.2 Participants 
The sample size was based on the work of (Polosa et al., 2017) who compared vapers with 
smokers. Using their data, 7 participants per group were needed to detect a 12% 
difference in FEV1 between groups with a power of 80% and a type-I error (alpha) of 0.05 
(5%). 
Participants were recruited from the local community and Manchester Metropolitan 
University through posters, social media channels and snowball sampling. The inclusion 
criteria were: 18- to 55-year-old men and women, and healthy cigarette smokers and 
vapers had to have smoked/vaped for ≥1 year. Exclusion criteria were: neuromuscular 
disease; severe musculoskeletal injuries; any lower limb injury; any diagnosed mental 
health disorder; treatment for chronic respiratory complaints; a known history of heart 
disease; smokers who mix cigarette and vape; water pipe (shisha) smokers. Vaping and 
smoking history and volume were assessed by a questionnaire. The smoking volume (SV) 
was given as pack years, calculated as: 
SV = (Ncig * S)/20 
Where Ncig is the current number of cigarettes smoked per day, and S the number of years 
smoked. It was assumed that 1 pack of cigarettes contained 20 cigarettes.  
2.3.3 Participant characteristics 
Demographic data including age, sex, height, body mass, body mass index (BMI) and 
occupation of participants was recorded. Height and body mass were assessed using a 
stadiometer and digital scales, respectively. Body composition was assessed using 
bioelectrical impedance (BodyStat 1500, BodyStat, Douglas, UK). 
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2.3.4 Carboxyhaemoglobin  
HbCO, which is the percentage of the haemoglobin (Hb) oxygen binding sites occupied by 
carbon monoxide (CO), was measured with a hand-held CO meter (Micro Smokerlyzer, 
Bedfont Scientific Ltd.; Kent, UK) according to the recommendations of the manufacturer 
(Hajek and Belcher, 1991). Participants exhaled to residual volume and then quickly 
inhaled until total lung capacity. After a 15-s breath-hold, the participants were asked to 
exhale slowly through a disposable mouthpiece attached to the carbon monoxide meter 
for at least 10 s. The measured HbCO level was expressed as percentage (HbCO%). 
2.3.5 Spirometry 
Spirometry was conducted using a Micro Medical Spiro USB Spirometer and analysed with 
Spida 5 software (Cardinal Health, UK).  FEV1, FVC, FEV1/FVC ratio, Peak Expiratory Flow 
(PEF), maximum mid-expiratory flow between 25% and 75% of the FVC (FEF25-75%) and 
predicted values of FVC, FEV1, FEF25-75% were recorded. The spirometry was completed in 
accordance with the American Thoracic Society/European Respiratory Society (ATS/ERS) 
guidelines (Miller et al., 2005). Predicted values were calculated by the Spida 5 software 
based on body mass index, age, sex and ethnicity according ATS/ERS guidelines. Each 
participant had a nose clip and completed a minimum of three manoeuvres with at least 
1–2 min rest between each manoeuvre. Manoeuvres were rejected if: participants 
prematurely stopped exhalation, coughed during the first second of exhalation, lips were 
not fully sealed around the mouthpiece, the mouthpiece was obstructed by the teeth or 
tongue and/or the effort appeared submaximal. The test session was concluded when the 
largest two FEV1  and the largest two FVC were each within 0.15 L of each other in at least 
3 manoeuvres (Miller et al., 2005). If these criteria were not met, the manoeuvres were 
repeated until the criteria were met, eight manoeuvres had been attempted, or if the 
participant did not want to continue. Participants were instructed not to eat heavy meals 
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or to smoke or vape and to refrain from vigorous physical activity for at least two hours 
before the test.  
2.3.6 Respiratory pressure 
The maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP) and sniff 
nasal inspiratory pressure (SNIP) were determined using a portable mouth pressure 
device (MicroRPM, Cardinal Healthcare, UK). The participants were asked to inhale 
(MIP/SNIP) or exhale (MEP) as forcefully as possible after full exhalation or inhalation, 
respectively into the portable MicroRPM. To determine SNIP, participants placed a probe 
in one of their nostrils, and with the other nostril closed inhaled as forceful as possible via 
the nose (Lofaso et al., 2006). For all manoeuvres, attempts were repeated, with a 30-s 
interval between each attempt to prevent the development of respiratory muscle fatigue, 
until a maximum value was reached. 
2.3.7 Statistics 
Statistical analyses were performed using SPSS 24.0 (IBM Corporation, NY, US). Data was 
assessed for normality with the Shapiro-Wilk tests. If the data were not normally 
distributed a two-way univariate ANOVA was performed on the log-transformed data. 
Differences between vapers, smokers and controls, and sexes were tested using 
univariate ANOVA with as between factors group and sex. If a significant group effect or a 
group * sex interaction were found, a Tukey 2-sided post-hoc test was performed to 
locate the significant differences.  Predicted spirometry values were compared between 
pure vapers (who never smoked), vapers who were ex-smokers and controls with a two-
way univariate ANOVA and Tukey-corrected post-hoc tests to locate the differences. A 
stepwise regression analysis was performed to assess to what extent spirometry 
parameters were affected by sex, and vaping or smoking duration or volume. Differences 
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and correlations were considered significant at p<0.05. All data are presented as 
mean±SD unless stated otherwise. 
 
2.4 Results 
Men were taller and heavier than women, and women had a higher fat percentage than 
men (p<0.05), irrespective of being vapers, smokers or controls (Table 2.1). All vapers had 
used e-cigarettes daily for ≥ 1 year (1.67±1.00 years). Eleven of the twelve vapers were 
using nicotine-containing e-liquids with a concentration ranging between 3 to 18 mg/mL. 
The puffs per e-cigarette were 8.30±5.23. Seven out of twelve vapers were former 
smokers, and the rest were pure vapers (only used vape exclusively). All cigarette 
smokers had smoked daily for 4.86±2.49 years, consumed 9.00±4.78 cigarettes/day and 
had a smoking history of 2.29±1.88 pack years. No group-sex interactions were found for 
any outcome measure, indicating that all the observed effects of smoking and vaping 
were similar in men and women. 
Men had higher FEV1, FVC, PEF, FEF25%, FEF50%, FEF25-75%, MIP and MEP than woman 
(p<0.05) (Table 2.2 and Figure 2.1 and 2.2). FEV1pred%, FEV1/FVC, FEF75%, FEF25-75pred%, SNIP 
and HbCO% did, however, not differ significantly between men and women (Table 2.2 
and Figure 2.1 and 2.2), but the FVCpred% was higher in women than men (Table 2.2; 
p<0.03).  
Vapers and cigarette smokers had lower FEV1, PEF, FEV1/FVC, FEF25%, FEF50%, FEF25-75%, 
FEF25-75pred% and higher HbCO% than controls (p<0.05) (Table 2.2 and Figure 2.1 and 2.2). 
The FEV1pred% was lower in smokers than controls (p<0.01), but there was no significant 
difference between vapers and controls (p=0.054) (Figure 2.1). Vapers had a lower FEF75% 
than controls (p<0.009), but there was no significant difference in FEF75% between 
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smokers and controls (p=0.064) (Figure 2.2). There were no significant differences in FEV1, 
FEV1pred%, PEF, FEV1/FVC, FEF25%, FEF50%, FEF75%, FEF25-75%, FEF25-75pred% and HbCO% 
between vapers and smokers (Table 2.2 and Figure 2.1 and 2.2). The FVC, FVCpred%, MIP, 
MEP and SNIP did not differ significantly between vapers, smokers and controls (Table 
2.2).  
A stepwise linear regression was performed to assess to what extent the respiratory 
parameters were determined by sex, height, body mass, smoking duration, smoking 
volume, or for vapers, vaping duration and number of puffs. Smoking duration was the 
primary determinants of FEV1pred% (R2adj=0.564; p=0.002), FEV1/FVC (R2adj=0.568; p=0.002), 
FEF50% (R2adj=0.412; p=0.011), FEF25-75% (R2adj=0.528; p=0.003), FEF25-75pred% (R2adj=0.665; 
p<0.001) (Figure 2.3). Vaping duration and number of puffs were not significant 
determinants of pulmonary function (Figure 2.3).  
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Vaping duration (years) 2.1±1.1 (6) 1.1±0.4 (6) - - - - 
Puffs per e-cigarette single 
use 
10.2±6.7 (5) 6.4±2.7 (5) - - - - 
Smoking duration (years) - - 5.4±2.9 (7) 4.1±1.7 (6) - - 
Cigarettes per day   9.3±5.8 (7) 8.6±3.4 (6)   
Smokers pack-years - - 2.7±2.3 (7) 1.7±1.0 (6) - - 
BMI: body mass index; (x): number of participants; *significantly different from men at p<0.05 




















 Men (6) Women (6) Men (8) Women (6) Men (9) Women (9)    
FVC (L) 4.94±0.62 3.58±0.50 4.81±0.87 3.67±0.34 5.37±0.034 3.90±0.58 0.19 <0.001 0.80 
FVCpred (%) 92.7±5.5 99.8±10.8 93.3±11.9 96.3±2.3 94.9±7.7 101.6±7.9 0.52 0.03 0.78 
FEF50% (L/s) 3.9±0.6 3.6±0.8 3.9±1.2 3.6±0.9 5.9±1.3 4.6±0.7 <0.001 0.044 0.24 
MIP (cmH2O) 107±40 (5) 62±13 (5) 101±48 (7) 74±19 (5) 107±8 (5) 79±28 (5) 0.83 0.007 0.78 
MEP (cmH2O) 110±36 (5) 74±7 (5) 93±49 (7) 78±20 (5) 126±32 (5) 76±17 (5) 0.52 0.007 0.45 
SNIP (cmH2O) 78.6±23.4 (5) 63.3±11.7 (5) 96.9±54.8 (7) 75.0±23.5 (5) 66.8±25.6 (5) 64.2±22.5 (5) 0.33 0.26 0.79 
HbCO (%) 1.02±0.27α 1.00±0.14α 1.68±0.92α 0.97±0.77α 0.00±0.00 0.00±0.00 <0.001 0.22 0.30 
All data are presented as (mean±SD); FVC: Forced vital capacity; FEF: Forced Expiratory Flow; MIP: Maximal inspiratory pressure; MEP: Maximal expiratory 
pressure; SNIP: Sniff nasal inspiratory pressure; HbCO: Carboxy-haemoglobin; (x): number of participants; α: significantly different from Control 




Figure 2.1: a) FEV1/FVC: Forced expiratory volume in one second/ forced vital capacity; b) FEV1: Forced expiratory volume in one second; c) FEV1 predicted: Forced 
expiratory volume in one second predicted %; d) PEF: Peak expiratory flow; * sex difference at p<0.001; α: significantly different from Control at p≤0.008 




Figure 2.2: a) FEF25%-75%: Forced expiratory flow at 25%-75%; b) FEF25%: Forced expiratory flow at 25%; c) FEF25%-75% (pred): Forced expiratory flow at 25%-75% predicted %; d) 
FEF75%: Forced expiratory flow at 75%;  * sex difference at p≤0.013; α: different from Control at p≤0.008 




















Figure 2.3: Relationship between respiratory parameters and smoking/vaping duration. a) FEV1/FVC: Forced 
expiratory volume in the first second/ forced vital capacity F; b) FEF25%-75% (pred): Forced expiratory flow at 
25%-75% predicted; c) FEV1pred%: Forced expiratory volume in one second predicted%. P-values for 
smokers in FEV1/FVC, FEF25%-75% (pred), FEV1pred% are 0.002, 0.003 and 0.003 respectively and for vapers 
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2.5 Discussion 
The main finding of this study was that smokers and vapers had a similarly lower 
respiratory function compared to people who neither smoked nor vaped, irrespective of 
sex. This was not related to respiratory muscle weakness, as reflected by similar maximal 
respiratory pressures in all groups. In addition, the HbCO content was similarly elevated in 
smokers and vapers. These data indicate that vaping and smoking may cause a similar 
degree of airway obstruction. 
In this study we confirmed that men have higher spirometric values, such as FEV1 and 
FVC, than women, as reported previously (Mead, 1980; Zakaria et al., 2019). Although it 
has been reported that cigarette smoking affects pulmonary function more in women 
than in men (Xu et al., 1994), the absence of any significant group-sex interaction 
indicated that in our study the effects of smoking and vaping described below were 
similar in men and women. 
Previous studies have also shown that vaping reduces lung function to a similar extent as 
smoking (Antoniewicz et al., 2019; Coppeta et al., 2018; Darabseh et al., 2020; Meo et al., 
2019), but other studies have reported no changes in pulmonary function parameters 
after vaping (Polosa et al., 2017; Staudt et al., 2018; Vardavas et al., 2012). The 
discrepancy between these studies might be due to the duration of e-cigarette use (i.e. 
years), whether participants were former smokers and/or the duration of smoking or 
frequency/intensity of vaping. Here we found that the duration of smoking was 
associated with a decline in respiratory function, but this was not the case for vaping. In 
fact, we observed that people who had been vaping for as little as 1.67 years had a similar 
decrement in lung function as those who had smoked for 4.86 years. This decline was not 
attributable to a previous smoking history in the vapers, as we found that there was no 
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significant difference in spirometry between pure vapers and vapers who were ex-
smokers. These decrements in spirometry measures are indicative of mild airway 
obstruction (McFadden Jr and Linden, 1972; Stockley et al., 2017). The increase in airflow 
resistance may be due to small airway narrowing consequent to mucosal oedema, 
smooth muscle contraction and/or local secretions as seen in long-term smokers 
(Vardavas et al., 2012) and may thus be an early sign of potential progression into 
obstructive lung diseases. 
Another explanation for low airflow could be reduced respiratory muscle strength. 
However, there were no significant differences between controls and vapers/cigarette 
smokers in maximal inspiratory and expiratory pressures. These findings suggest that the 
reduced airflow during smoking/vaping is a consequence of obstruction of the airways 
rather than lower respiratory muscles strength. We have seen previously that elevated 
HbCO results in an earlier onset of muscle fatigue (Morse et al., 2008) and it can therefore 
not be excluded that during exercise respiratory muscle fatigue may impair lung function 
in smokers and vapers.  
Limitations of this study include the small sample size, although power calculations 
indicated that the sample size was large enough to detect 12% differences in FEV1. 
Perhaps a larger problem is that some of the participants were ex-smokers, but even in 
vapers who had no smoking history a lower-than-expected lung function was observed. 
Further studies are needed to compare vapers who never smoked with smokers and 
assess the effects of smoking and vaping cessation on ventilatory function. 
2.6 Conclusion 
While neither vaping nor smoking had a significant impact on respiratory muscle strength, 
both vaping and smoking led to a similar obstruction of the airways, independent of sex. 
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The elevated HbCO in both vapers and smokers may further compromise respiratory 
function during exercise. These observations indicate that vaping has similar detrimental 
effects on pulmonary function as smoking and suggest that one should treat the 
suggestion that vaping is 95% healthier than smoking with caution (McNeill et al., 2015). 
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Chapter 3 : Fourteen days of smoking cessation improves muscle 
fatigue resistance and reverses markers of systemic inflammation 
 
 
Part of this chapter has been published as: 
Darabseh, M.Z., Maden-Wilkinson, T.M., Welbourne, G., Wüst, R.C., Ahmed, N., 
Aushah, H., Selfe, J., Morse, C.I. and Degens, H., 2021. Fourteen days of smoking 
cessation improves muscle fatigue resistance and reverses markers of systemic 
inflammation. Scientific reports, 11(1), pp.1-11. 
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3.1 Abstract: 
Background: Cigarette smoking has a negative effect on respiratory and skeletal muscle 
function and is a risk factor for various chronic diseases. 
Objective: To assess the effects of 14 days of smoking cessation on respiratory and 
skeletal muscle function, markers of inflammation and oxidative stress in humans. 
Methods:  Spirometry, skeletal muscle function, circulating carboxyhaemoglobin levels, 
advanced glycation end products (AGEs), markers of oxidative stress and serum cytokines 
were measured in 38 non-smokers, and in 48 cigarette smokers at baseline and after 14 
days of smoking cessation. 
Results: Peak expiratory flow (p=0.004) and forced expiratory volume in 1 second/forced 
vital capacity (p=0.037) were lower in smokers compared to non-smokers but did not 
change significantly after smoking cessation. Smoking cessation increased skeletal muscle 
fatigue resistance (p<0.001). Haemoglobin content, haematocrit, carboxyhaemoglobin, 
total AGEs, malondialdehyde, TNF-α, IL-2, IL-4, IL-6 and IL-10 (p<0.05) levels were higher, 
and total antioxidant status (TAS), IL-12p70 and eosinophil numbers were lower (p<0.05) 
in smokers. IL-4, IL-6, IL-10 and IL-12p70 had returned towards levels seen in non-smokers 
after 14 days smoking cessation (p<0.05), and IL-2 and TNF-α showed a similar pattern 
but had not yet fully returned to levels seen in non-smokers. Haemoglobin, haematocrit, 
eosinophil count, AGEs, MDA and TAS did not significantly change with smoking 
cessation. 
Conclusion: Two weeks of smoking cessation was accompanied with an improved muscle 
fatigue resistance and a reduction in low-grade systemic inflammation in smokers. 
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3.2 Introduction: 
Cigarette smoking is still a public health concern and a risk factor for many chronic 
diseases, including chronic obstructive pulmonary disease (COPD), lung cancer and 
cardiovascular diseases  (Health and Services, 2010; Warren et al., 2014). It is the leading 
cause of preventable death and 77,900 deaths in the United Kingdom were directly or 
indirectly attributable to smoking in 2016 (Office for National Statistics, 2017). In England, 
between 2017 and 2018, an estimated 489,300 smoking-related admissions to hospitals 
were reported (Lifestyles Team, 2019). 
The adverse health effects are a consequence of a combination of thousands of toxic 
and/or carcinogenic substances, including carbon monoxide (CO), reactive glycation 
compounds, known as glycotoxins, and nicotine in cigarette smoke (Cerami et al., 1997; 
Glantz et al., 1998; Harris, 1996). In addition, the low-grade systemic inflammation and 
oxidative stress in smokers increases the risk of atherosclerosis (Abdul-Rasheed and Al-
Rubayee, 2013; Aula and Qadir, 2013; Bloomer, 2007; Lykkesfeldt et al., 2004; Morrow et 
al., 1995). Smoking is associated with elevated serum cholesterol and triglyceride levels, 
impaired glucose tolerance and reduced insulin sensitivity (Frati et al., 1996). It has been 
reported that in diabetic people, a reduced insulin sensitivity could lead to glycation of 
myofibrillar proteins (Syrový and Hodný, 1992) that may be further aggravated by 
glycotoxins in cigarette smoke that can also react with serum proteins to form advanced 
glycation end products (AGEs) (Cerami et al., 1997). 
In addition to the health burden of cigarette smoking and the potential adverse effect on 
respiratory function (Darabseh et al., 2020; Stănescu et al., 1996), smoking can also have 
a negative impact on muscle function (Degens et al., 2015; Morse et al., 2007; Sadaka et 
al., 2021; Wüst et al., 2008c). Part of the potential detrimental effect of cigarette smoking 
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may be attributable to the negative impact on the oxygen delivery to tissues, including 
skeletal muscles, that may in turn result in exercise intolerance and a reduced muscle 
fatigue resistance (Larsson et al., 1998; Prior et al., 2004; Sadaka et al., 2021; Wüst et al., 
2008a). Such an impaired oxygen delivery is at least partly attributable to the CO in the 
cigarette smoke that strongly binds to haemoglobin (Hb), forming carboxyhaemoglobin 
(COHb) (Pojer et al., 1984). This not only reduces the oxygen carrying capacity of the 
blood, but also causes a left-shift of the Hb-dissociation curve. The significance of 
elevated COHb levels has been illustrated by an acute CO-induced reduction in muscle 
fatigue resistance in healthy people (Morse et al., 2008). In addition, CO and cyanide may 
also directly impair mitochondrial respiration (Ajime et al., 2021; Alonso et al., 2003). As 
fatigue resistance was similar in COPD patients who had quit smoking and healthy age-
matched non-smokers (Degens et al., 2005), we hypothesised that the effect of smoking 
on skeletal muscle fatigue is readily reversible by smoking cessation in healthy smokers. 
Smoking cessation is an important step to stop or reverse many of the detrimental effects 
of smoking and is considered a highly effective way to reduce morbidity and mortality 
(Rodrigues et al., 2014) and slow down the accelerated decline in FEV1 (Anthonisen, 1997; 
Kanner et al., 1999). In fact, smoking cessation is considered one of the main actions to 
attenuate the  progression of COPD (American Thoracic Society, 1999; Faulkner et al., 
2006). The focus of this chapter will be on the effects of smoking and SC on respiratory 
function, muscle function and inflammatory markers. This is because it has been reported 
previously that the smoking-induced lung inflammation, mitochondrial dysfunction, limb 
and diaphragm muscle atrophy, and elevated IL-1α and TNF-α levels were normalised 
after smoking cessation in mice (Ajime et al., 2021; Braber et al., 2010). In addition, if CO 
is an important cause of a reduced muscle fatigue resistance and exercise tolerance, we 
expect that smoking cessation, resulting in a quick normalisation of the COHb levels 
54 | P a g e  
 
(Kambam et al., 1986), will be associated with a concomitant improvement in muscle 
function. Therefore, we hypothesise, that just two weeks of smoking cessation is 
sufficient to detect measurable improvements in muscle fatigue resistance, and 
diminished levels of circulating inflammatory markers and oxidative stress. As there is 
some indication that smoking may cause a larger reduction in pulmonary function than in 
men (Xu et al., 1994) and that women have a higher muscle fatigue resistance than men 
(Wüst et al., 2008b) we were also interested in potential sex differences in the response 




Cigarette smokers (men n=28; women n=20) and non-smokers (men n=23; women n=15) 
were recruited from the local community and Manchester Metropolitan University 
(MMU). Healthy participants were 18 to 44 years old, and smokers had smoked for ≥ 1 
year and ≤ 17 years. All participants self-reported as being free of symptoms of chronic 
diseases. In cigarette smokers, all measurements were repeated after 14 days of smoking 
cessation. The study was approved by the Science and Engineering Research Ethics and 
Governance Committee at MMU (Ethics reference number: 5944) and performed in 
accordance to the principles stated in the Declaration of Helsinki. All participants 
provided written informed consent before participating. 
 Height and body mass were assessed using a stadiometer and digital scales, respectively. 
Body mass index (BMI) was calculated. Smoking history was assessed by questionnaire. 
Smoking volume (SV) was given as pack years, calculated as the current number of packs 
of cigarettes smoked per day times the number of years smoked. 
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3.3.2 Outcome measures 
 
3.3.2.1 Carboxyhaemoglobin (COHb) 
A hand-held CO meter (Micro Smokerlyzer, Bedfont Scientific Ltd.; Kent, UK) was used to 
measure the percentage of the haemoglobin (Hb) oxygen binding sites occupied by CO 
(%COHb). The measurements were performed according to the recommendations of the 
manufacturer (Hajek and Belcher, 1991).  
 
3.3.2.2 Spirometry 
Spirometry was conducted using a Micro Medical Spiro USB Spirometer and analysed with 
Spida 5 software (Cardinal Health, UK). Spirometry was completed in accordance with the 
American Thoracic Society and European Respiratory Society guidelines (Miller et al., 
2005). Each participant completed a minimum of three successful manoeuvres with at 
least 1–2 min rest between each manoeuvre while wearing a nose clip. The manoeuvres 
were rejected if: participants prematurely stopped exhalation, coughed during the first 
second of exhalation, lips were not fully sealed around the mouthpiece and/or the effort 
appeared submaximal. The test session was concluded when the largest two FEV1 and the 
largest two FVC were each within 0.15 L of each other in at least 3 manoeuvres (Miller et 
al., 2005). If these criteria were not met, a maximum of eight manoeuvres were repeated 
until the criteria were met. Parameters assessed included: FEV1, FVC, FEV1/FVC ratio, Peak 
Expiratory Flow (PEF), and predicted values. The coefficient of variation (CV) for FEV1, FVC 
and PEF was 2.09%, 2.25% and 2.80%, respectively. 
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3.3.2.3 Maximal voluntary contraction (MVC) 
A dynamometer chair was used to measure the MVC during knee extension (Figure 3.1). 
Participants were seated with the hip joint in 90° flexion, knee joint angle at 80° and the 
pelvis strapped to minimise accessory movements. All the measurements were 
performed on the right thigh. During the MVC, participants received verbal 
encouragement and visual feedback of the torque signal (Degens et al., 2005; Morse et 
al., 2008; Morse et al., 2007; Wüst et al., 2008c). Participants performed the MVC twice 
with two minutes rest between each contraction to prevent development of fatigue. Knee 
extensor (KE) torque was recorded with a digital acquisition system (Acknowledge, Biopac 
Systems, Santa Barbara, CA, USA) at 200 Hz, and the highest value was reported as 
maximal muscle strength (Morse et al., 2007). The KE muscles (quadriceps) was used as 
this group of muscles is important for locomotion and hence important for most activities 
of daily living. The CV for the MVC was 4.24%. 
 
3.3.2.4 Voluntary activation (VA) and muscle fatigue resistance 
To assess the VA and muscle fatigue resistance of the quadriceps muscle, carbon-rubber 
pads (7.5 cm x 13 cm, Axelgaard, USA) were used to apply percutaneous electrical 
stimulation (square wave, pulse width 200 μs; DSV Digitimer Stimulator, Digitimer Ltd., 
Herts, UK). The cathode was placed over the distal third of the thigh and the anode over 
the proximal part of the quadriceps. The electrical stimulation voltage was set at 400 V. 
To assess the supra-maximal current, single pulses were administered at 30-s intervals 
with increases in current of 50-100 mA to the relaxed muscle until no further increase in 
torque was noticed. 
To assess the VA during an MVC, the interpolated twitch technique was used (Morse et 
al., 2007; Wüst et al., 2008c) and  calculated as: 
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VA (%) = (1-(superimposed twitch torque/resting twitch torque))*100 
and had a CV of 5.96%. 
The fatigue resistance of the quadriceps muscles was determined by a series of 
electrically-evoked isometric 30-Hz trains, 1 s on 1 s off, for 2 min at a current that elicited 
30% MVC at the start of the test  (Degens et al., 2005; Wüst et al., 2008c). The fatigue 
index (FI) was calculated as the final torque as a percentage of the initial torque during 














Figure 3.1: Dynamometer chair for Muscle function testing 
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3.3.2.5 Haematology parameters and oxidative stress biomarkers  
Nine non-smokers and 20 smokers consented to provide blood samples. Venous blood 
was collected from the antecubital vein and repeated after 2 weeks of smoking cessation 
from smokers only. After determination of the haematocrit (%Hct) the blood was 
collected in 4-mL vacutainers without anticoagulants (BD Vacutainer, Becton Dickinson 
Company, USA). The blood samples were allowed to clot for 15 minutes and serum was 
separated from whole blood by centrifugation (20 min; 500 x g) at room temperature. 
Following centrifugation, the serum was aliquoted in 1-mL microcentrifuge tubes, frozen 
and stored at -80°C until further analysis.  
Serum protein, albumin and glucose concentrations were measured colourimetrically 
using Biuret reagent Randox kits using RandoxRX Daytona analyser (Randox Laboratories 
Ltd., Belfast, Ireland). The glucose concentration was determined after enzymatic 
oxidation in the presence of glucose oxidase. The Hb concentration was determined with 
a HemoCue (HemoCue® Hb 201+ System). Blood cell counts included agranulocytes 
(lymphocytes, monocytes) and granulocytes (neutrophils, eosinophils and basophils). 
Serum cytokines levels were quantified using flow cytometry. Briefly, positive and 
negative controls were used to set up the flow cytometer (BD FACScalibur, Becton 
Dickinson Company, USA) and analysed using the high flow setting (FL2 channel), using 
Cell Quest Pro software and flowcytomix software. The software translated the flow 
cytometric results into cytokine concentrations (pgmL-1). Serum malondialdehyde (MDA), 
a marker of lipid peroxidation, was quantified spectrophotometrically using a lipid 
peroxidation kit (Oxford Biomedical Research, UK). The serum total antioxidant status 
(TAS) was analysed using the TAS kit (Randox Laboratories Ltd., Belfast, Ireland) according 
to the recommendations by the manufacturer. The abundance of low molecular weight 
(LMW) AGEs were assessed using a spectrofluorimeter (BioTek, USA), and total AGEs 
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were assessed by ELISA (Cell Biolabs, United States). All tests were carried out in duplicate 
and averaged.  
 
3.3.3 Statistical Analysis  
Statistical analyses were performed using SPSS 24.0 (IBM Corporation, NY, US). Data were 
assessed for normality with the Shapiro-Wilk tests. If the data were not normally 
distributed, non-parametric Kruskal-Wallis H test was performed. A two-way univariate 
ANOVA with as between factors group (smokers, non-smokers and smoking cessation) 
and sex was used. If a significant group effect, or a group * sex interaction was found, a 
Dunnet post-hoc test with as standard group the smokers was performed to locate the 
significant differences. For the blood parameters, comparisons between smokers and 
non-smokers, and comparison of smokers before and after cessation were performed 
with unpaired student t-tests. Differences were considered significant at p<0.05. All data 
are presented as mean±SD.  
 
3.4 Results: 
Anthropometric details of the participants are presented in Table 3.1. The smoking 
women in our study had smoked longer and had smoked more pack years than the 
smoking men (p<0.05; Table 3.1). For none of the parameters group * sex interactions 
were found, indicating that there were no significant differences in the responses to 
smoking and smoking cessation between men and women. 
The total protein, albumin and glucose concentrations did not differ significantly between 
smokers and non-smokers (Table 3.2). Smokers had higher levels of COHb than non-
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smokers (p<0.001) and the COHb levels had returned to levels similar to that in non-
smokers after 14 days of smoking cessation (Table 3.3). 
 
3.4.1 Spirometry 
PEF, FEV1 and FVC were higher in men than women (p<0.001), but FEV1/FVC, FEV1pred%, 
FVCpred% and PEFpred% did not differ significantly between men and women (Table 3.4). 
There was no significant difference in FEV1, FEV1pred%, FVCpred% and PEFpred% between 
smokers and non-smokers (Table 3.4), but PEF (p=0.004; Table 3.4) and FEV1/FVC 
(p=0.037; Figure 3.2) were lower in smokers than in non-smokers. Neither changed 
significantly over the 14 days of smoking cessation (p>0.05; Figure 3.4 and Table 3.4). 
 
3.4.2 Muscle function 
Knee extension MVC was higher in men than women (p<0.001; Table 3.4) and FI was 
higher in women than men (p<0.001), but there were no significant sex differences in VA 
(p=0.096; Table 3.4). There was no significant difference in MVC and VA between smokers 
and non-smokers (Table 3.4). While there was no significant difference in FI between 
smokers and non-smokers, smoking cessation resulted in an increased FI (p≤0.036; Figure 
3.3a-b). An example of the torque reduction during a series of electrically evoked 
isometric contractions is shown in figure (3.4). 
 
3.4.3 Haematology 
There were no significant differences in total white blood cell, neutrophil, lymphocyte, 
monocyte and basophil counts between smokers and non-smokers (Table 3.3). The 
eosinophil count was lower in smokers than non-smokers (p<0.05) even after 14 days 
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smoking cessation (Table 3.3). Smokers had a higher haemoglobin concentration and 
haematocrit than non-smokers (p<0.001) and was not changed significantly after 14 days 
of smoking cessation (Table 3.3). 
 
3.4.4 Circulating markers of oxidative stress  
The total antioxidant status was lower in smokers than non-smokers (p<0.001) and was 
not significantly changed after 14 days of smoking cessation (Figure 3.5a). Lipid 
peroxidation, in the form of the concentration of MDA was higher in smokers compared 
to non-smokers (p<0.001) and were not significantly changed after 14 days of smoking 
cessation (Figure 3.5b). Although the low molecular weight AGE levels did not differ 
significantly between smokers and non-smokers (Figure 3.5c), the total AGE levels were 
higher in smokers compared to non-smokers (p<0.05; Figure 3.5d). Smoking cessation did 
not have a significantly alter the concentration of AGEs (Figures 3.5c and 3.5d). 
 
3.4.5 Circulating levels of cytokines 
Smokers had higher circulating levels of TNF-α, IL-2, IL-4, IL-6 and IL-10 levels than non-
smokers (All p<0.001; Figures 3.6a-e), while IL-12p70 levels were lower in smokers than in 
non-smokers (p<0.001; Figure 3.6f). Almost all circulating cytokines concentrations 
returned to levels seen in non-smokers after 14 days of smoking cessation, except for 
TNF-α and IL-2 that though reduced, where still elevated in comparison to non-smokers 
(p<0.05; Figures 3.6a and 3.6b). TNF-β, IFN-γ, IL-1β, IL-5 did not differ significantly 
between smokers and non-smokers (Table 3.5).   
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Table 3.1: Demographic data. All data are presented as mean±SD; BMI: body mass index; *: 
significantly different from men at p<0.05 









Age (Years) 25.4±6.0 31.0±12.8* 26.3±10.5 24.8±7.4 
Height (m) 1.78±0.09 1.65±0.09* 1.79±0.07 1.65±0.06* 
Mass (kg) 77.5±17.7 67.9±11.4* 77.3±11.6 68.2±14.2* 
BMI (kg/m2) 24.2±4.5 25.1±4.0 24.1±3.1 24.8±4.3 
Smoking duration (years) 7.4±4.3 13.7±12.2* - - 
Cigarettes per day 12.3±6.0 12.7±5.7 - - 
Smokers pack-years 4.6±2.9 9.6±11.0* - - 
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 Table 3.2: Smoking or smoking cessation did not alter total protein, albumin and glucose serum concentration. All data are presented as mean±SD; C: 








Stop smoking  
n=20 
Statistical evaluation (p-value) 
S vs. C S vs. SC SC vs. C 
Total protein 
(g/L) 
65.4±2.3 66.0±3.5 64.5±2.7 NS NS NS 
Albumin 
 (g/L) 
43.4±2.8 45.7±2.4 44.7±2.3 NS NS NS 
Glucose  
(mmol/L) 
5.14±0.75 5.10±0.34 5.33±1.03 NS NS NS 
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Table 3.3: The impact of smoking and smoking cessation on white blood cell counts, haematocrit, haemoglobin and carboxyhaemoglobin. All data are 
presented as mean±SD; WBC: White blood cells; Hct: Haematocrit; COHb: Carboxyhaemoglobin; C: Non-smokers; S: smokers; SC: 14 days smoking 
cessation; NS: not significant. 
 





Stop smoking  
n=20 
Statistical evaluation (p-value) 
S vs. C S vs. SC SC vs. C 
WBC (109/L) 6.70±2.16 6.98±1.97 6.89±1.70 NS NS NS 
Granulocytes 
Neutrophil (%) 54.6±4.80 60.3±12.1 58.9±8.50 NS NS NS 
Eosinophil (%) 3.44±0.87 2.24±1.03 2.25±0.98 <0.05 NS <0.05 




34.3±3.60 30.5±11.18 32.2±8.05 NS NS NS 
Monocyte (%) 6.0±1.23 5.58±1.39 5.58±1.30 NS NS NS 
Haematocrit, haemoglobin and carboxyhaemoglobin 
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Hct (%) 41.0±4.6 46.5±2.6 45.6±2.6 <0.001 NS <0.01 
Haemoglobin 
(g/dL) 
13.7±1.80 15.5±0.89 15.3±0.89 <0.001 NS <0.01 
COHb (%) 0.07±0.03 2.26±1.08 0.1±0.28 <0.001 <0.001 NS 
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Table 3.4: The effect of smoking and smoking cessation on spirometry, maximal isometric voluntary knee extension torque (KE MVC) and voluntary 
activation (VA). All data are presented as mean±SD; FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; PEF: Peak expiratory flow; 




Group Sex FEV1 
(L) 
FEV1pred (%) FVC  
(L) 





















































































































Smoke  NS NS NS NS 0.004 NS NS NS 
Sex  <0.001 NS <0.001 NS <0.001 NS <0.001 NS 
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 Table 3.5: The impact of smoking and smoking cessation on circulating cytokines. All data are presented as mean±SD; TNF-β: tumour necrosis factor-










Statistical evaluation (p-value) 
S vs. C S vs. SC SC vs. C 
TNF-β  82.9±31.2 109.0±34.0 109.1±46.8 NS NS NS 
IFN-γ  139±82 144±57 161±55 NS NS NS 
IL-1β  100.4±53.0 109.4±38.4 94.1±41.3 NS NS NS 
IL-5  109±89 125±57 132±30 NS NS NS 
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Figure 3.2: The effect of smoking and 14 days smoking cessation on 
FEV1/FVC: Forced expiratory volume in one second/forced vital capacity; 






























Figure 3.3: The effect of smoking and 14 days smoking cessation on fatigue index.  
Data are mean±SD; ∞: significantly different from men at p<0.05; α: significantly  
different from smokers at p<0.05. 
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Figure 3.5: Effects of smoking and 14 days smoking cessation. a) Total antioxidant status (TAS); b) 
Malondialdehyde concentration; c) Low molecular weight (LMW) advanced glycation end products (AGEs) 
fluorescence; d) AGEs concentration; data are mean±SD; *: significantly different from Non-smokers at 
p<0.05. 
Figure 3.4: Example of the torque reduction during a series of electrically evoked isometric contractions. The torque at 2 
min (last contraction) divided by the peak torque during the first contraction is given as the fatigue index, where a higher 












Figure 3.6: Effects of smoking and 14 days smoking cessation .a) TNF-α: tumour necrosis factor-
alpha; b) IL-2: interleukin-2; c) IL-4: interleukin-4; d) IL-6: interleukin-6; e) IL-10: Interleukin-10; f) 
IL-12p70: interleukin-12p70; data are presented as mean±SD; *: significantly different from Non-
smokers at p<0.05; α: significantly different from smokers at p<0.05. 
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3.5 Discussion  
To our knowledge, the current study is the first to assess the effects of 14 days of smoking 
cessation on lung function, muscle function, inflammatory markers and cytokines in 
healthy smokers. The main observation of the present study was that in smokers with 
normal spirometry 14 days of smoking cessation resulted in a normalisation of skeletal 
muscle fatigue resistance and a return of circulating markers of inflammation. This 
indicates that as little as 14 days of smoking cessation can confer measurable benefits 
that may encourage smokers in their smoking cessation efforts.  
 
3.5.1 Differences between smokers and non-smokers 
3.5.1.1 Spirometry 
The present study confirms that FEV1, FVC and PEF were higher in men than women 
(Crapo et al., 1981). The spirometry in smokers was similar to that of non-smokers, except 
for a lower FEV1/FVC, indicative of some minor developing airway obstruction. 
 
3.5.1.2 Muscle function 
In line with previous observations (Larsson and Örlander, 1984; Morse et al., 2007; Wüst 
et al., 2008c), we found that the maximal strength of the knee extensor muscles in 
smokers was similar to that in non-smokers. Others, however, have reported a lower 
force generating capacity in smokers (Al-Obaidi et al., 2004; Barreiro et al., 2010; 
Örlander et al., 1979; Seymour et al., 2010). Although part of a lower strength may at 
least in theory be attributable to a lower ability to voluntarily activate the muscle, we 
found no difference in voluntary activation between smokers and non-smokers, and if 
anything, even an increased VA has been reported in smokers (Wüst et al., 2008c). The 
latter may be the result of an increased sympathetic nerve activity in smokers, possibly 
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due to a central stimulant action of nicotine (Mündel and Jones, 2006; Narkiewicz et al., 
1998). Whatever the cause of the discrepancy between studies concerning the impact of 
smoking on the MVC, it indicates that smoking per se is not necessarily associated with 
muscle weakness. 
Somewhat unexpected was the absence of  lower fatigue resistance in smokers that was 
seen in previous studies using the same fatigue protocol (Morse et al., 2007; Wüst et al., 
2008c). This reduced fatigue resistance in the previous smokers was thought to be at least 
partly attributable to elevated COHb levels, seen also in the current and other studies 
(Pojer et al., 1984; Wald et al., 1981) that not only reduces the oxygen carrying capacity, 
but also the release of oxygen due to the left-shift of the Hb-dissociation curve (Degens et 
al., 2015; Morse et al., 2008). It should be noted, however, that 6% COHb reduced 
skeletal muscle fatigue resistance (Morse et al., 2008) and the 3% COHb in our 
participants may not have had a measurable impact on the oxygen delivery to the skeletal 
muscle, and hence the fatigue resistance. 
  
3.5.1.3 Blood parameters  
While we did not see a significant difference in the albumin and total protein 
concentrations in the blood of smokers and non-smokers, others did see that smokers 
had a lower total protein and albumin concentration compared to non-smokers (Alsalhen 
and Abdalsalam, 2014) or even a higher protein concentration (Alhemieri, 2008). 
Consistent with previous studies (Malenica et al., 2017; Nordenberg et al., 1990; Shah et 
al., 2012), the haemoglobin concentration and haematocrit were higher in smokers 
compared to non-smokers. The higher haemoglobin concentration may well be an 
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adaptation to maintain the oxygen carrying capacity in the face of elevated COHb levels 
(Aitchison and Russell, 1988; Roethig et al., 2010). 
Although there were no significant differences in monocytes and lymphocytes between 
smokers and non-smokers in the current and previous studies (Malenica et al., 2017; 
Tulgar et al., 2016), except for a reduction in the number of eosinophils, we observed a 
significant increase in TNF-α, IL-2, IL-4, IL-6 and IL-10. This suggests that smoking activates 
mononuclear cells to release cytokines. In line with this, it has been observed that 
cigarette smoke induces the release of TNF-α in an in vitro macrophage model system 
(Demirjian et al., 2006), but others found no increased release of TNF-α peripheral blood 
mononuclear cells to cigarette smoke extracts (Ouyang et al., 2000). It should be noted, 
however, that TNF-α is not only produced by blood mononuclear cells, but also by 
epithelial cells, fibroblasts and smooth muscle cells (Brenner and Miller, 2014, p.229) and 
perhaps mononuclear and epithelial cells in the lung of smokers (Lee et al., 2012). In line 
with this, it has been observed that there was a significantly elevated number of 
macrophages and neutrophils in the broncheo-alveolar lavage fluid of smoking mice 
(Ajime et al., 2021). Therefore, lung-derived cytokines may well be the prime explanation 
of the higher TNF-α, IL-2, IL-4, IL-6 and IL-10 concentrations and the lower level of the 
anti-inflammatory IL-12p70 concentration in smokers than non-smokers, indicating that 
even young-adult asymptomatic smokers suffer from a low-grade systemic inflammation. 
It is possible that the lower TAS and higher MDA levels in smokers, also reported by 
others (Mahmood et al., 2007), may be due to this low-grade systemic inflammation. The 
oxidative stress in smokers may well have contributed to their elevated AGE levels 
(Cerami et al., 1997; Moldogazieva et al., 2019; Vlassara and Palace, 2002). Although 
AGEs are often considered to represent indirectly a high level of glucose (Goldin et al., 
2006; Singh et al., 2014), we and others (Alhemieri, 2008) did not find elevated glucose 
75 | P a g e  
 
levels in smokers. It should be noted that not only high glucose concentrations, but also 
toxic constituents of cigarette smoke might induce glycotoxins that rapidly react with 
protein to form AGEs (Cerami et al., 1997). Therefore, we suggest that the increased AGEs 
in asymptomatic young-adult smokers is primarily attributable to glycotoxins, oxidative 
stress, and to some extent secondary to the low-grade systemic inflammation. 
 
3.5.2 Smoking cessation 
3.5.2.1 Spirometry 
The present study showed that 14 days of smoking cessation did not result in an 
improvement in the smoking-induced decrement of FEV1/FVC. This is supported by 
numerous studies suggesting that pulmonary changes induced by smoking are 
irreversible, even though smoking cessation is the best approach to stop the accelerated 
decline in lung function in smokers (Aparici et al., 1993; Buist et al., 1979; Burchfiel et al., 
1995; Fletcher and Peto, 1977; Lange et al., 1989; Pezzuto et al., 2013). 
 
3.5.2.2 Muscle function  
In support of our hypothesis, we found an improved skeletal muscle fatigue resistance 
after 14 days of smoking cessation that was accompanied with a return of the COHb 
levels to that seen in non-smokers. It therefore does appear that the improved fatigue 
resistance after smoking cessation was at least to some extent attributable to an 
improved oxygen delivery, and perhaps also improved mitochondrial function. Indeed, 2 
weeks smoking cessation has been shown to improve mitochondrial function in mouse 
muscle, although in mice this was not accompanied by an improved muscle fatigue 
resistance (Ajime et al., 2021). Nevertheless, our data suggest that even in smokers with 
only 3% COHb smoking cessation can still enhance muscle fatigue resistance, even when 
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the fatigue resistance was not significantly less than that in non-smokers. Perhaps the 
enhanced fatigue resistance after smoking cessation is to some extent also attributable to 
the elevated haemoglobin concentration and haematocrit that enhance the oxygen 
carrying capacity and oxygen delivery with smoking cessation even above that seen in the 
non-smokers (Aitchison and Russell, 1988; Degens et al., 2015), similar to that seen after 
doping with erythropoietin (Rasmussen et al., 2010). In addition, smoking cessation also 
improves exercise-induced vasodilation (Celermajer et al., 1993; Johnson et al., 2010). 
Overall, our data indicate that even smoking cessation for as short a period as 2 weeks 
can result in measurable improvements in muscle fatigue resistance.  
 
3.5.2.3 Blood parameters  
Another significant observation in our smokers was evidence of low-grade systemic 
inflammation and oxidative stress. It was therefore particularly interesting to assess the 
impact of smoking cessation on these parameters. Here we found that most of the 
abnormal blood parameters were normalised by 14 days of smoking cessation. 
The present study showed that both TAS and MDA did not return to normal levels after 
14 days of smoking cessation. This may occur later as it has been shown that after 28 days 
of smoking cessation, TAS was increased and MDA levels reduced back to normal levels 
(Polidori et al., 2003). AGE levels also did not show a significant decrement after 14 days 
of smoking cessation. The 3-week half-life of AGEs (Ahmed et al., 2002; Biemel et al., 
2002; Klöpfer et al., 2011) may explain that despite the diminished low-grade systemic 
inflammation AGEs remained elevated. Therefore, 14 days of smoking cessation might 
not be long enough to cause a normalisation in TAS, MDA and AGEs to levels similar to 
that in non-smokers. 
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Smoking cessation interrupts the exposure to chemicals in cigarette smoke (Rodrigues et 
al., 2014)  and it is likely that the reduced concentration of smoking-related chemicals in 
the blood that induce inflammation will result in a reduction in cytokine levels 
(Helmersson et al., 2005; McCarty, 1999; Mio et al., 1997). For example, the elevated 
levels of TNF-α after 20 weeks smoking was back to baseline levels after 8 weeks smoking 
cessation in the broncho-alveolar lavage fluid of mice (Braber et al., 2010) and similarly 30 
days smoking cessation resulted in a significant reduction in TNF-α in humans (Rodrigues 
et al., 2014). Here we showed that IL-6, IL-10, IL-12p70, IL-4 returned to normal levels and 
TNF-α was reduced after 14 days of smoking cessation. It has been suggested that the 
lungs are the primary cause of the low-grade systemic inflammation in patients with 
chronic obstructive pulmonary disease (Gan et al., 2004). In line with this it has been 
shown that 2 weeks smoking cessation in mice led to a return in the number of leucocytes 
in the broncheo-alveolar lavage fluid to normal levels (Ajime et al., 2021). Eosinophil 
numbers remained lower in smokers than non-smokers after 14 days of smoking 
cessation, which may be secondary to the higher concentration of IL-2 in smokers, even 
after 14 days of smoking cessation.  
 
3.5.3 Future directions 
We showed significant improvements in muscle fatigue resistance and inflammatory 
status that may well be sufficient to stimulate smokers in their attempts to quit smoking. 
Future studies are recommended to conduct longer duration of smoking cessation 
programmes with larger sample size to assess whether also the markers of oxidative 
stress and circulating AGEs return to normal values. Although it remains to be seen to 
what extent the effects observed are related to the duration of smoking, in our previous 
work we have shown that at least the lower fatigue resistance in smokers was not related 
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to the duration of smoking or smoking pack years. It remains to be seen what the clinical 
significance of these changes is may be. 
  
3.6 Conclusion 
Even in smokers with normal spirometry there is significant evidence of oxidative stress 
and systemic inflammation. A short period of smoking cessation of just 2 weeks is enough 
to improve the inflammatory status to almost back to normal levels and induce an 
improvement in muscle fatigue resistance. These benefits will undoubtedly stop the 
progression of detrimental effects of low-grade systemic inflammation and encourage 
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4.1 Abstract 
Background: Smoking is a well-known health risk for many chronic diseases including 
cardiovascular diseases and respiratory disorders. Smokers try to quit using several 
strategies including electronic cigarette use (vaping). An alternative, easy and cheap 
method is exercise. However, little is known about the efficacy of aerobic exercise to 
augment vaping cessation (quit vaping) and smoking cessation. 
Objective: To systematically review and discuss the reported effects of aerobic exercise 
on long-term vaping and smoking cessation in randomized control trials. 
Methods: This review was registered on the PROSPERO database. Randomized control 
trials on MEDLINE, AMED, SPORTDiscus, CINHAL and PEDro databases were searched 
from 1st January 1970 to 1st January 2021. The primary outcome was long-term vaping 
cessation or smoking cessation (≥ 6months). Secondary outcome measures included 
maximal or peak oxygen uptake (VO2max/peak) after vaping- or smoking cessation. Meta-
analysis was conducted to examine the effects of aerobic exercise on long-term vaping 
cessation and smoking cessation, and the effects of aerobic exercise on VO2max/peak. 
Cochrane Risk of Bias tool 2 was used to assess trial quality.  
Results: Thirteen trials were included in this review (5 high, 2 moderate and 6 low 
quality). Although two high quality trials revealed that 3 vigorous supervised aerobic 
exercise sessions a week for 12 to 15 weeks increased the number of long-term successful 
quitters, the meta-analysis including the other trials showed that aerobic exercise did not 
significantly increase success rate of long-term quitters. However, VO2max/peak was 
improved at the end of treatment. There were no trials on aerobic exercise and vaping 
cessation.  
Conclusion: No evidence was found that aerobic exercise promotes long-term smoking 
cessation. Nevertheless, aerobic exercise improved VO2max and/ or VO2peak in quitters. 
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Keywords:  Aerobic exercise, Smoking, Smoking cessation, Vaping, Vaping cessation, 
Systematic review and Meta-Analysis 
4.2 Background 
Smoking is considered the main risk factor for the development of preventable diseases 
such as cancers, cardiovascular diseases and respiratory disorders, including chronic 
obstructive pulmonary disease (COPD), and globally seven million deaths per year are 
attributable to smoking (World Health Organization, 2017). Smoking cessation (SC) 
reduces the risk of hospitalization due to chronic conditions, such as COPD, and is 
associated with significant life extensions (Taylor Jr et al., 2002; Tran et al., 2015). As the 
annual death rate attributable to smoking is expected to increase within the next 
decades, the World Health Organization started calling upon governments and health 
institutes to develop anti-smoking regulations and interventions to further promote SC 
(World Health Organization, 2017). 
Although approximately 40% of smokers make at least one quit attempt annually (Control 
and Prevention, 2008), only fewer than 5% succeed (Etter et al., 1997). Electronic-
cigarette use (vaping) is promoted as a harmless and safe alternative to cigarette smoking 
(Dutra et al., 2017) and uptake of vaping has been reported to be associated with higher 
rates of SC (Rahman et al., 2015; Tackett et al., 2015). Vaping may, however, not be as 
harmless as originally thought and has been reported to cause similar detrimental effects 
on lung and cardiovascular function as smoking (Darabseh et al., 2020). Such harmful 
effects may well contribute to the reportedly 33% of vapers that are willing to visit a 
vaping cessation (quit vaping) service if available in their neighbourhood (Etter, 2019).  
Beside vaping, SC interventions vary from pharmacotherapies including nicotine 
replacement therapy and SC counselling (Lemmens et al., 2008) to meditation and yoga 
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programmes (Bock et al., 2012). However, the success of these interventions is influenced 
by many factors such as the dose, type and duration of medication, intervention or 
counselling, motivational skills of SC advisors, follow-up periods, smokers’ adherence, 
duration of smoking and number of cigarettes one used to smoke per day. Indeed, the 
long-term effectiveness of these interventions remains ambiguous (Ahluwalia et al., 2002; 
Aubin et al., 2008; Cooper et al., 2005; Gariti et al., 2009) and it is essential to keep 
looking for other interventions and assess their effectiveness. 
One such potential alternative SC intervention is aerobic exercise. Exercise interventions 
are categorised as e.g. aerobic, strengthening or relaxation exercises. As vaping and 
smoking particularly affect the cardiovascular and respiratory systems we consider here 
the impact of aerobic exercise training on the success of vaping cessation (quit smoking) 
and smoking cessation. Aerobic exercise refers to exercise where the ATP demands can 
be met by aerobic metabolism alone (Kisner et al., 2017). 
When people quit smoking, they might suffer from anxiety, depression and low mood 
(West and Hajek, 1997), factors that may be alleviated by aerobic exercise and thereby 
contributing to the often-reported exercise-induced improvement in the quality of life 
(Dunn et al., 2005; Legrand and Heuze, 2007; Norris et al., 1990; Senkfor and Williams, 
1995; Steptoe and Cox, 1988). Perhaps even more important is that aerobic exercise, such 
as walking, cycling or running, is easy to access and cheap and therefore a viable 
intervention to facilitate SC, particularly via the reduction of nicotine withdrawal 
symptoms and cigarette craving (Roberts et al., 2012; Taylor et al., 2007). 
The mechanism by which aerobic exercise may enhance SC is not fully clear, but a number 
of mechanisms have been postulated, including raised endorphins, distraction and 
increased self-efficacy. It is known for example, that aerobic exercise induces an increase 
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in plasma β-endorphins (De Meirleir et al., 1986) that is dependent on the intensity and 
duration of the exercise performed (Goldfarb et al., 1990). The exercise-induced rise in β-
endorphin levels may be significant as it has been found that higher levels were 
associated with fewer smoking relapses after cessation (Shaw and al'Absi, 2008). 
Additional mechanisms whereby aerobic exercise may facilitate SC are 1) increased 
proprioceptive input  due to larger and more frequent movements that could distract 
smokers from cigarette craving (Wai et al., 2011) and 2) improved image self-efficacy 
(Loprinzi et al., 2015). Despite these potential mechanisms, the long-term benefits of 
exercise for smoking- and vaping- cessation are not clear. 
When prescribing or describing exercise interventions, it is important to consider the 
frequency, intensity, time and type (FITT) of exercise (Brown et al., 1978; Franklin et al., 
2003; Sasso et al., 2015). The benefits of exercise training for vaping cessation and 
smoking cessation may well depend on the duration, intensity and frequency of exercise 
training. As it is unclear whether aerobic exercise facilitates SC, a systematic review 
evaluating the effects of different exercise prescriptions (including the FITT principle) for 
vaping- and smoking cessation is warranted. Therefore, the aim of this review is to assess 
the effectiveness of aerobic exercise interventions on long-term vaping cessation and SC, 





The main question of this study is: Does aerobic exercise helps to quit smoking and 
vaping? To answer this question, the objectives of the study were to review and discuss 
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the reported effects of aerobic exercise on long-term vaping cessation and smoking 
cessation, and to conduct a meta‐analysis for the included trials.  
 
4.3.2 Design 
The study was designed to provide a systematic review with quality assessment, narrative 
synthesis, and meta-analysis of relevant published literature. 
 
4.3.3 Study protocol 
The protocol of this systematic review is registered in the International prospective 
register of systematic reviews database (PROSPERO) (registration number: 
CRD42021232759; 02 February 2021; URL: 
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=232759) 
 
4.3.4 Search strategy 
The following electronic databases were searched for trials published between 1st January 
1970 to 1st January 2021: EBSCO host database including MEDLINE, AMED, SPORTDiscus 
and CINHAL; and PEDro. These databases were chosen because of the likely availability of 
exercise-related trials in these databases. Reference lists of included trials were hand 
searched to identify other potentially relevant trials. Trials included were limited to those 
written in English and published in peer-reviewed journals. Results of the searches were 
managed using Endnote Version X7 (Clarivate Analytics, Philadelphia, PA). 
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4.3.5 Keywords  
Search terms were adapted to meet the search requirements of each electronic database. 
The keywords used were structured according to the PICOS approach (population, 
intervention, comparison, outcome measures and study design) (Schardt et al., 2007). 
Table 4.1 summarizes the combinations of keywords included in the search strategies. 
PICOS search terms were combined using Boolean operators ‘AND’ and ‘OR’. The search 
was limited to randomised controlled trials (RCTs). To allow reproducibility of the search, 
the Medical Subject Headings (MeSH) were used. 
Table 4.1: Keywords and search strategy used, using the PICOS approach in the selected 
databases. 
 Population Intervention Comparison Outcome 
measures 



































































































Final search=S1 AND S2 AND S3  
 
4.3.6 Inclusion/exclusion criteria for the trials 
Inclusion criteria:  
Trials were included if: 
• they included men & women >18 years old 
• they assessed continued/prolonged vaping cessation/smoking cessation by means 
of objective measures such as carbon monoxide (CO), cotinine and/or thiocyanate 
level 
• participants had been smoking ≥5 cigarettes per day for ≥6months or vaped for 
≥6months and were not diagnosed with airways obstruction. 
• the intervention was aerobic exercise, such as brisk walking, cycling, treadmill 
walking, running, stationary cycling, rowing, aerobic gym exercises, or any other 
type of exercise where the ATP demands can be met by aerobic metabolism 
(Kisner et al., 2017). 
 
Exclusion criteria:  
Trials were excluded if: 
• the intervention was other than cardiovascular/aerobic exercise, or if the aerobic 
exercise was combined with another type of exercise 
• the exercise type used was not identified 
• the outcome measures did not include CO, cotinine and/or thiocyanate 
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• the period of vaping/smoking cessation was less than six months 
• not written in English language 
• participants were diagnosed with psychiatric illness that could affect their exercise 
adherence (for example: depression or anxiety) 
• there were substance misuse problems (such as drugs and alcohol abuse) 
• participants were pregnant 
• participants suffered from any medical condition that might affect their exercise 
performance such as musculoskeletal or neurological conditions 
• published protocols were presented but without published data/results, or if they were 
conference abstracts 
 
4.3.7 Study Selection 
The first reviewer (MD) retrieved all trials from initial database searches and imported 
these into Endnote software. Trials were screened for suitability by the first reviewer 
(MD) by consulting the title and abstract against the pre-defined eligibility criteria for 
potential full-text review. The second reviewer (AA) independently screened the trials by 
consulting titles and abstracts against the pre-defined eligibility criteria for potential full 
text review.  
 
4.3.8 Risk of Bias and Quality Assessment of the Included trials 
Risk of bias of included trials was assessed using the Cochrane Risk of Bias tool 2 (CROB 
2). Two review authors independently assessed the risk of bias. The following were 
assessed using the CROB 2: (1) bias arising from the randomization process; (2) bias due 
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to deviations from intended interventions; (3) bias due to missing outcome data; (4) bias 
in measurement of the outcome; (5) bias in selection of the reported result. 
Two review authors independently assessed the quality of the included trials using the 
PEDro Scale, a validated tool for assessment of quality of interventional trials specifically 
related to physiotherapy interventions (de Morton, 2009; Maher et al., 2003). The PEDro 
scale contains 11 items, and trials are awarded between 0 and 10 points, depending on 
the number of criteria they meet (the first item is not used to calculate the summary 
score). Trials with scores of four points or more are classified as “high‐quality”, whereas 
trials with three points or fewer are classified as “low‐quality” (de Morton, 2009; Maher 
et al., 2003). PEDro and CROB 2 scores for the trials were not used as inclusion or 
exclusion criteria, but as a basis for best‐evidence synthesis and to determine the 
strengths and weaknesses of each trial. 
 
4.3.9 Data Extraction 
The following data were extracted from the included trials: author name(s); year of 
publication; sample size; age; intervention for each group; outcome measures; 
comparator group; duration of the follow-up period; number of participants at baseline; 
number of participants who remained abstained at the final follow-up period; 
intervention for each group, including exercise prescription component (frequency, 
intensity, time and type of exercise); the physiological effect of aerobic exercise on 
cessation (e.g. increases in maximal and/or peak oxygen uptake) after vaping/smoking 
cessation.  
Extracted data were consulted and checked with the second reviewer (AA). 
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4.3.10 Outcome measures 
The main outcome measure was the proportion of participants who successfully quit 
vaping or smoking for at least six months, verified by objective measures such as CO, 
cotinine and/or thiocyanate concertation at the last/longest period of assessment (follow 
up). 
Where reported, the physiological effect of aerobic exercise was included in the review, 
e.g. increases in maximal and/or peak oxygen uptake (VO2max/peak) after vaping/smoking 
cessation. 
 
4.3.11 Measurement of treatment effect 
The risk ratio (RR) was calculated as = (quitters in exercise group/total randomised to 
exercise group)/(quitters in control group/total randomised to control group), with a 95% 
confidence interval (CI). Where more than one exercise group was included, the sum of 
the participants in all exercise groups was compared with the sum of all participants in all 
control (non-exercise) groups. 
Standardised mean differences and their 95% CI were calculated from the data generated 
by each included randomised controlled trial for VO2max or VO2peak results. Forest plots 
were used to present the effectiveness of exercise on vaping- and smoking cessation, and 
the effects of aerobic exercise on VO2max or VO2peak, using the OpenMetaAnalyst software.  
Where statistical pooling was not possible, the findings were presented in narrative form. 
 
4.3.12 Dealing with missing data 
All data that were available in the included trials were included in the Meta-analysis with 
intention-to-treat. 
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4.3.13 Heterogeneity assessment  
After pooling data from the trials, statistical heterogeneity was determined using the I2 
statistic (Higgins et al., 2003). I2 <50% indicates low heterogeneity.  
 
4.4 Results  
4.4.1 Results of the search 
The systematic search identified 527 articles, 85 of which were duplicates. After screening 
the titles and abstracts, 367 publications were considered not relevant. Of the 75 
remaining trials, 62 were excluded: 10 were using combined exercises, or combined 
exercise and diet management; 3 included participants with diagnosed depression; 11 did 
not include objective smoking cessation measures (such as CO, cotinine, or thiocyanate); 
28 did not include aerobic exercise or did not specify the type of exercise used; in 5 the 
follow up on the effects of aerobic exercise was <6 months; 3 aimed for smoking 
reduction not cessation; 1 only conducted exercise counselling but not exercise and 1 trial 
presented preliminary results for an already included full trial. Consequently, 13 trials 
were included. All the included trials included healthy smokers who were not diagnosed 
with airway obstruction, except one included trial participants with acute myocardial 
infarction (Taylor et al., 1988). Figure 4.1 shows the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) flow-chart for the included/excluded 
search records. Table 4.2 is the data extraction table for the included 13 trials. No 
disagreement was encountered between the first and second reviewer in study selection.  
Appendix 10 shows all the excluded records from the systematic search.  
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4.4.2 Risk of bias and quality assessment  
Five trials were at low risk of bias (low risk of bias across all domains, or low risk of bias in 
four domains and one domain with “some concern”), six trials were at high risk of bias 
(high risk of bias in at least one domain), and the remaining two at unclear/some concern 
of risk of bias. A summary of the CROB2 results is shown in Figure 4.2.   
The PEDro scale results revealed that the included trials were of high quality (total PEDro 
score >4 points), with most of the trials scoring 6 points. Only one trial scored 5 (Taylor et 
al., 1988), as groups were not similar at baseline. Three trials scored 7 (Bize et al., 2010; 
Marcus et al., 2005; Prapavessis et al., 2016), because allocation of participants was 
concealed.  No disagreement was encountered between the first and second reviewer in 
terms of risk of bias assessment.   
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Figure 4.2: the PRISMA flow-chart for the search records and the included trials. 
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Intervention/s (for each group) 
FITT (where possible) 
Outcome 
measures  











21:40 G1: 12-week group supervised 
exercise intervention (12 one 
session a week) + Telephone 
counselling SC intervention that 
included TNP (8 sessions, 
weekly, 20-min each) + exercise 
group counselling/discussion 
weekly (for 12 weeks, for 20 
min) + unsupervised aerobic 
exercise sessions. 
Exercise began before quitting 
date 
 
G2: 12 weeks SC counselling 
sessions: (12 sessions, 1hr each) 
+ Telephone counselling SC 
intervention that included TNP 
(8 sessions, weekly, 20 min 
each). 
 
For exercise prescription:  
F: Once a week exercise 
supervised session + two to four 
unsupervised exercise sessions a 
week. 
I: Moderate exercise (range of 











utilizing 10 ppm 







No significant difference in 
abstinence between groups 
(p=0.18). 
 
Participants in G1 had 
higher verified cessation 
rates (EOT: 30.0% in G1 vs. 
25.8% in G2), and 12-month 
follow-up (13.3% in G1 vs. 
3.2% in G2).  
 
VO2peak was increased 
similarly in both groups:  
G1: baseline=27.8 (5.8) 
ml/kg/min, EOT=30.0 (5) 
ml/kg/min G2: 
Baseline=26.2 (9.6) 
ml/kg/min, EOT=27.3 (6) 
ml/kg/min. 
 
At EOT, adherence in both 
G1 and G2 was 9.3 ± 2.8 
vs. 9.3 ± 3.0 out of the 12 
sessions, respectively. 
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T: Began at 20 min per session 
with weekly gradual increases, 
to 100 min midway through the 
intervention up to 150 min 
towards the ends of the 
intervention. 
T: Treadmill, stationary bicycles, 
walking, running, sports, cycling 
and housework 














G1: 9-week exercise group 
supervised intervention (9 
sessions-once a week) + 15 min 
individual based SC intervention 
and counselling sessions weekly 
(for 9 weeks) including NRT 
products prescription such as 
TNP, gum, inhaler and lozenge + 
unsupervised exercise sessions. 
Exercise started 1 week before 
quitting date 
 
G2: 9-weeks SC individual based 
SC intervention weekly (9 
sessions) for 15 min session 
including NRT products 
prescription such as TNP, gum, 
inhaler and lozenge + 9-weeks 
60-minute supervised group 
sessions health education 
(discussions, lectures etc).  
 
For exercise prescription:  
F: One supervised exercise 
Follow-up at 10, 26 
and 52 weeks after 
the beginning of 






utilizing 10 ppm 




The intensity of 
exercise was 
monitored 
with the Borg 
Rating of Perceived 
Exertion Scale 
Participation in a weekly 
population-based 
programme of moderate-
intensity exercise for 9 
weeks was not sufficient to 
increase SC rate when 
added to a comprehensive 
SC programme offering 
individual counselling and 
NRT. 
 
Continuous cessation rates 
were high and similar in G1 
and the G2 at the EOT (47% 
vs 46%, p=0.81), and 
similarly decreased at 26 
weeks (34% vs 35%, p=0.77) 
and at 1-year follow-up 
(27% vs 29%, p=0.71), 
respectively. 
 
At 52-weeks follow-up, the 
adherence in G1 
was 55% and in G2 62%. 
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session a week + four 
unsupervised (home based) 
sessions a week 
I: Moderate exercise (intended 
to target 40% - 60% of maximal 
aerobic power)  
T: 45 min per session supervised 
and 30 min unsupervised 
exercise sessions. 
T: Brisk walking and slow 
jogging, commuting on foot or 
by bicycle, leisure/ recreational 
and aerobic housework 
activities. 












10:26 G1: 5-week supervised (if 
participants’ circumstances 
allowed, if not, they were asked 
to do unsupervised sessions) 
exercise intervention (10 
sessions-twice a week) + group 
SC counselling sessions twice a 
week (for 5 weeks) for 60-90 
min per session + unsupervised 
exercise sessions 
Exercise began on the quitting 
date. 
 
G2: 5-weeks group SC 
counselling intervention twice a 
week (total of 10 sessions) for 
60-90 min per session  
 
For exercise prescription:  
Assessment 
occurred at 
baseline, 5 weeks 
(EOT), follow-up: 1, 





utilizing 10 ppm 






No significant difference in 
quit rate between G1 and 
G2 (p=NS) 
 
G1 VO2max significantly 
increased from 30.28 
ml/kg/min at baseline to 
32.11 ml/kg/min at EOT 
(p<0.05), compared to G2 
who have slight increase 
from 30.52 ml/kg/min to 
30.9 ml/kg/min (p=NS). 
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F: Twice a week group session + 
as often as possible times 
unsupervised sessions a week 
I: Not specified  
T: 30 min per session supervised 
and as long as possible 
unsupervised  
T: Bicycle ergometer, walk or 
jog, bicycle ride, running, walk 
up and down of stairs 




G1 = 22 
G2= 22  
G3= 18 
G4= 20 
Total= 59 39:43 G1: Behavioural treatment only  
G2: Behavioural treatment 
combined with nicotine gum  
G3: Behavioural treatment 
combined with supervised or 
unsupervised physical exercise  
G4: Supervised or unsupervised 
physical exercise 
 
For G3 and G4 exercises 
prescription:  
F: 3 Supervised or unsupervised 
sessions a week for 12 weeks 
I: 60% - 70% of HR reserve 
T: 45 minutes 
T: graduated walking (indoor 
and outdoor) 
Quit rates were 
assessed at EOT 
and at 4, 7, and 12 
months as follow 




utilizing 10 ppm 




At 12 months the 
proportion of quitting 
across groups were 
(G1=31.8%, G2=36.4%, 
G3=27.8%, and G4=10.0%) 
indicating that behavioural 
training facilitated cessation 
(G1, G2 and G3) better than 
the physical exercise only 
(G4) (p<0.01). 
 
The adherence rates were: 
G1 65%; G2 66%; G3 57% 














0: 263 G1: Aerobic exercise supervised 
sessions + SC counselling 
sessions (once a week for 19 
weeks) + nicotine gum + home 
based exercise sessions (e.g., 
walking, exercise tapes) to bring 
Quit rates were 
assessed at EOT 
and at follow-up: 1 
week, 1, 4 and 12 
months 
 
G1 and G2 at EOT and 12 
months follow-up had a 
similar rate of cessation as 
G3 (p=NS) 
 
The increase in VO2max from 
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their total number of weekly 
exercise sessions to at least 
three. 
 
G2: SC counselling sessions 
(once a week for 19 weeks) + 
nicotine gum + health education 
sessions and discussions  
G3: SC counselling sessions 
(eight session over the 19 
weeks) + nicotine gum 
 
Participants were followed from 
3 weeks before cessation to 
1year post cessation. 
For G1 exercise prescription:  
F: Twice a week for 5 weeks, 
then once a week for 14 weeks 
+ home based exercise sessions 
(30 mins) to bring their total 
number of weekly exercise 
sessions to at least three 
I: 60% - 80% HRmax 
T: 40 mins 





utilizing 10 ppm 
cut-off at each 
assessment time 







baseline to EOT was 
significantly higher in G1 
than G2 and G3 (p<0.05): 
G1: baseline=28.8 (8.5) 





G3: baseline= 34.2 (5.8) 
ml/kg/min, EOT=35.3 (6.9) 
ml/kg/min. 
 
The combined pre and 
post cessation adherence 
rates were higher in G2 













0:20 G1: Aerobic exercise group 
supervised sessions + SC 
counselling sessions (twice a 
week for 4 weeks) 
G2:  SC counselling only (twice a 
week for 4 weeks) 
Exercise began before quitting 
Quit rates were 
assessed at EOT 
and at follow-up: 1, 




Four participants in G1 
remained abstinent at 1 
month, 3 participants at 3 
months and 2 participants 
at 12 months after SC 
treatment, compared with 
zero in G2 (p<0.05). 




For G1 exercise prescription:  
F: 3 supervised exercise sessions 
a week for 15 weeks 
I: 70% - 85% HRmax 
T: 30-45 minutes 
T: cycle ergometry and treadmill 
walking 
 
saliva cotinine < 10 
ng/ml  
 
VO2max cycle test 
 
 
Only in G1 VO2max was 
increased (p<0.01) 
G1: baseline=26 (6) 
ml/kg/min, EOT=31 (3) 
ml/kg/min 
G2: baseline=26 (5) 
ml/kg/min, EOT=26 
(2)ml/kg/min (No increase 
nor decrease). 
 
Adherence rate was only 
mentioned for G1 and was 












0:20 G1: Aerobic exercise group 
supervised + SC counselling 
sessions (once a week for 12 
weeks) 
G2: SC counselling sessions 
(once a week for 12 weeks) + 
health education 3 times a week 
(for 45 mins each) for 12 weeks  
Exercise began before quitting 
date 
 
For G1 exercise prescription:  
F: 3 a week supervised exercise 
sessions for 12 weeks 
I: 70% - 85% HRmax  
T: 30 - 40 minutes 
T: cycle ergometry and treadmill 
walking 
 
Quit rates were 
assessed at EOT 
and at follow-up: 1, 
3, 12 months. 
 
SC Self-reports 
verified by expired 
CO (utilizing 8 ppm 
cut-off at each 
assessment time 
point) and  
saliva cotinine < 10 
ng/ml 
 
VO2max cycle test 
There were no significant 
differences at EOT in favour 
of the G1 over G2 (4 vs. 2 
participants).  
 
At 1- and 3-months follow-




At the 12-month follow-up, 
three of G1 participants 
remained abstinent. One 
participant only in G2 
remained abstinent  
 
All three participants of G1 
who were abstinent at 12 
months had continued 




The increase in VO2max was 
higher in G1 than G2 
(P<0.05): 
G1: baseline=24 (4) 
ml/kg/min, EOT=30 (4) 
ml/kg/min. 
G2: baseline=28 (6) 
ml/kg/min, EOT=27 (1) 
ml/kg/min. 
 
At EOT, adherence rate: 
G1: 85% of the smoking 
cessation sessions; 88% of 
the exercise sessions 
G2: 85% of the smoking 
cessation sessions; 92% of 









G1= 40.7 (9.1) 
G2= 29.7 (8.8) 
0: 281 G1: Aerobic exercise groups 
supervised sessions + SC 
counselling sessions (once a 
week for 12 weeks). 
G2: SC counselling sessions 
(once a week for 12 weeks) + 
health education (45 - 60 mins 
each) 3 times a week for 12 
weeks. 
Exercise began before quitting 
date 
 
For G1 exercise prescription:  
F: 3 a week supervised exercise 
Quit rates were 
assessed at EOT 




verified by expired 
CO (utilizing 8 ppm 
cut-off at each 
assessment time 
point) and  
saliva cotinine < 10 
ng/mL 
 
G1 participants were more 
likely than G2 participants 
to be continuously 
abstinent during the 8 
weeks of treatment 
following quit day (19.4% vs 
10.2%, P=0.03).  
 
G1 participants were more 
likely than G2 participants 
to achieve 3 and 12 months 
of continuous abstinence 
following quit day (3 
months: 16.4% vs 8.2%, 
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sessions for 12 weeks 
I: Vigorous 60% - 85% HR 
reserve 
T: 40 - 50 mins 
T: cycle ergometry and treadmill 
walking 
 
VO2peak cycle test 
 
P=0.03; 12 months: 11.9% 
vs 5.4%, P=0.05). 
 
The increase in VO2peak was 
higher in G1 than G2 
(p<0.01): 
G1: baseline=25 (6) 
ml/kg/min, EOT=28 (6) 
ml/kg/min. 
G2: baseline=25 (5) 
ml/kg/min, EOT=25 (5) 
ml/kg/min (No increase nor 
decrease). 
 
At EOT, adherence rate for 
G1 was 68.7%, and for G2 
64.6%. 
At 12 months follow-up, 
adherence rate for G1 was 












0:217 G1: Aerobic exercise groups 
supervised sessions + home 
based exercise 4 times a week 
for 30 mins each + SC 
counselling sessions (1hr, once a 
week for 8 weeks).  Offered 
nicotine patch. 
G2: SC counselling sessions (1hr, 
once a week for 8 weeks) + 
health education (1hr, once a 
week for 8 weeks). Offered 
nicotine patch. 
Exercise began before quitting 
Quit rates were 
assessed at EOT 




verified by expired 
CO (utilizing 8 ppm 
cut-off at each 
assessment time 
point) and  
saliva cotinine < 10 
ng/ml 
No significant differences 
between G1 and G2 at EOT 
and 3 months follow up 
(14.7% and 7.3% for G1 vs. 
11.1% and 3.7% for G2, 
p=NS, respectively).  
 
No group differences were 
found at 12 months follow 
up of continues cessation 
(0.09% for G1 vs. 0.09% for 
G2, p=0.75), where both 
groups were equally likely 




For G1 exercise prescription:  
F: One session a week for 8 
weeks 
I: Moderate, 45% - 59% HR 
reserve or 50% - 69% of HRmax 
T: 55 minutes 











to report SC at EOT 
 
The increase in VO2max was 
significantly higher in G1 
than G2 (P<0.05): 







At EOT, adherence for G1 
was 54.1% and for G2 
58.9%. 
At 12 months follow up, 
adherence for G1 was 
24.8% and for G2 31.8%. 
Prapavessis 


















0: 142 Phase 1: 6 weeks 
G1: Supervised exercise 
programme  
G2: Supervised cognitive 
behavioural SC programme (3 
times a week for 5 weeks) 
 
Phase 2: 7 - 12 weeks, 121 
participants who made a quit in 
phase 1, were randomised to 1 
of 4 groups in phase 2: 
G1: Aerobic group exercise + SC 
counselling (3 times a week for 
6 weeks) 
G2: Aerobic group exercise + 
Quit rates were 
assessed at EOT 




verified by expired 
CO (utilizing 10 
ppm cut-off at 
each assessment 
time point) and  




For continuous abstinence, 
no significant differences 
between groups were 
noted at the three post-quit 
time periods. 
 
At 3-month follow-up and 
12-month follow-up, 33.9% 
and 22.0% of those who 
received patches compared 
to 25.8% and 11.3% of 
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nicotine patches 
G3: Cognitive behavioural 
cessation programme (3 times a 
week for 6 weeks) 
G4: Cognitive behavioural 
cessation programme (3 times a 
week for 6 weeks) + nicotine 
patches. 
Exercise began before quitting 
date 
 
For exercise prescription:  
F: Three times a week for 12 
weeks 
I: 60% - 75% HR reserve   
T: 45 minutes 








At EOT, participants who 
received the nicotine 
patches (irrespective of 
group) were more likely to 
remain abstinent (72.9% vs. 
53.2%) (p=0.03). 
 
At EOT, G1 had significantly 
increased their PWC 
compared to G2 (p<0.01) 
 
At EOT, adherence for 
G1+G2 was 62.4% of the 
exercise sessions and for 
G3+G4 62.8% of their 
smoking cessation sessions. 
Prapavessis 

















0:413 Participants completed a 14-
week exercise programme with 
NRT (TNP).  
NRT started after 4 weeks of 
exercising.  
 
Then randomised to 1 of 4 
groups  
G1: Exercise maintenance 
(group supervised) + SC 
maintenance 
G2: Exercise maintenance 
(group supervised) + contact 
control  
Quit rates were 
assessed at EOT 
and at follow-up: 




verified by expired 
CO (utilizing 6 ppm 
cut-off at each 
assessment time 
point) 
At week 26, there was no 
significant difference in the 
proportion of abstainers 
(p=0.77) 
 
At week 56, there were no 
significant differences in the 
cessation rates between G1 
(32.8%), G2 (19%), G3 
(27.6%) and G4 (20.7%) 
(p=0.43) 
 
At EOT, adherence G1 was 
50.93%; G2 53.15%; G3 
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G3: SC maintenance+ contact 
control 
G4: Contact control 
G1+G2 during weeks 8 - 14 
received cognitive behavioural 
therapy sessions in groups, five 
sessions a week for 25-min with 
the goal of teaching self-
regulatory skills and for exercise 
adherence. Also, during weeks 
26 and 52 they received 
telephone counselling seven 
sessions for 15-min biweekly 
(for the first month), then 
monthly (for the next 2 months) 
and then bimonthly (for last 8 
months). 
 
G3+G4 contacted by messages 
reinforcing women’s health 
issues. Also, during weeks 26 
and 52 they were contacted by 
messages reinforcing the 
Forever Free booklets and/or 
women’s health issues. 
 
For exercise prescription:  
F: First 8 weeks three sessions a 
week, weeks 9 - 11 two sessions 
a week and weeks 12 - 14 only 
one session + unsupervised at 
weeks 8 - 14 three sessions a 
week similar to the supervised 
49.33% and G4 45.26%. 
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duration and intensity. 
I:  70% - 75% HRmax   
T: 45 minutes supervised. 15 
minutes unsupervised 
T: Treadmills, rowing machines, 
stair climbers and stationary 
bicycles 






Total= 28 (7) 
 
0:42 One week (4 1hr sessions) 
behavioural smoking cessation 
program, then randomly 
assigned into: 
G1: Group aerobic exercise class 
sessions + home based (2 
sessions) 
G 2: Group SC counselling 
including health education (1hr 
each, 9 sessions) 
G3: Control group (reports 
weight, CO and withdrawal 
symptoms) 
 
Exercise began after quitting 
date 
 
For exercise prescription:  
F: 3 sessions a week (one 
supervised and two 
unsupervised) for 9 weeks 
I:  70% - 80% HRmax   
T: 20 - 30 mins 
T: Cycling, walking, jogging and 
home-based aerobic exercises. 
Quit rates were 
assessed at EOT 




verified by expired 
CO 
 
PWC 150 cycle 
ergometer test 
EOT cessation rates were 
high (83% irrespective of 
group) for all groups at the 
end of the program 
 
 
There were no significant 
differences in cessation 
across groups; the cessation 
rates were decreased from 
83% at the EOT to 73% at 3 
months, 49% at six months 
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Total= 52 (9) 68:0 Started as 
G1: Supervised aerobic exercise 
followed by home based 
exercise training (54) + one SC 
counselling session (at week 3 
post AMI) 
G2: Supervised aerobic exercise 
followed by medically 
supervised group exercise 
training (53) + one SC 
counselling session (at week 3 
post AMI) 
G3: Supervised aerobic exercise 
only (26) + one SC counselling 
session (at week 3 post AMI) 
G4: Control (Participants were 
seen for the first time at 26 
weeks for aerobic exercise 
testing) (27)  
 
Ended up as 
G1+G2 pooled to be exercise 
group 
G3+G4 pooled to be non-
exercise group 
 
For exercise prescription:  
Not available in the text.  
Quit rates were 
assessed at EOT 





verified by plasma 
thiocyanate, 
utilizing 100 
mmol/L as cut-off  
 
Functional capacity 
treadmill peak test 
12% (5/42 participants) in 
the G1 and 19% (5/26 
participants) in G2 were still 
smoking at 3 weeks. 
 
None of the 10 participants 
who were smoking at 3 
weeks 
stopped by 26 weeks 
(p=NS) 
 
By 23 weeks, cessation 
rates were 69% (29/42) in 
G1 and 61% (16) in G2, 
respectively. 
 
Between week 3 and 26 
significant improvement in 
VO2peak level in exercise 
groups compared to non-
exercise group (average 
increase of 6.65 ml/kg/min 
vs. 4.2 ml/kg/min 
respectively (p<0.05)). 
G1: Group 1; G2: Group 2; G3: Group 3; G4: Group 4; M: Man; W: Women; SC: Smoking cessation; NS: Not significant; FITT: Fitness, 
Intensity, Time, Type; VO2max: maximum oxygen uptake; VO2peak: peak oxygen uptake; TNP: Transdermal nicotine patch; EOT: End of 
treatment; CO: Carbon monoxide; NRT: Nicotine replacement therapy; HR: Heart rate; PPM; parts per million; PWC: Physical work 
capacity; AMI: Acute myocardial infarction. 
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4.4.3 Meta-analysis results:  
Effectiveness of aerobic exercise to facilitate smoking cessation  
To assess the effectiveness of aerobic exercise to facilitate smoking cessation, 12 trials 
comparing exercise groups to non-exercise groups were subjected to a meta-analysis 
(Figure 4.3). One trial of moderate quality could not be used for the analysis, as they did 
not report the number of participants, or proportion of the total number of participants 
in each group (Russell et al., 1988). The meta-analysis showed that aerobic exercise did 
not significantly enhance the success rate of SC (Figure 4.3). 
 
Effects of exercise during smoking cessation interventions on VO2max and/or VO2peak 
A meta-analysis of 5 trials (three high, one moderate and one low quality) (Abrantes et 
al., 2014; Marcus et al., 1999; Marcus et al., 1991; Marcus et al., 1995) showed that 
aerobic exercise during smoking cessation interventions resulted in a higher VO2max 
and/or VO2peak than the other groups post intervention (Figure 4.4). No significant 
heterogeneity was found. The other trials were not included in the meta-analysis as they 
did not report mean and standard deviations for VO2max and/or VO2peak for each group. 
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Figure 4.4: Forest plot for the success of Smoking cessation (SC). CI: confidence interval; Ev: number of quitters in the exercise group/s at the last 
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Figure 4.5: Forest plot for the trials on the effects of the intervention on maximal oxygen uptake (VO2max and/or VO2peak). CI: confidence interval. 
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4.5 DISCUSSION 
This thesis showed detrimental effects of smoking and vaping on respiratory function, 
muscle function and inflammatory biomarkers and the benefits of smoking cessation 
(chapters 2 and 3). It was therefore important to consider interventions that might help 
the success of smoking cessation efforts, and one such factor might be aerobic exercise. 
This systematic review and meta-analysis are the first to review the literature on the 
benefits of aerobic exercise for long-term vaping cessation and SC, and its effects on 
VO2max and/or VO2peak. The review included a meta-analysis of 13 trials which assessed the 
effectiveness of aerobic exercise interventions on long-term SC and VO2max and/or 
VO2peak. The main finding of this review was that there is no evidence that aerobic 
exercise enhances long-term SC. Nevertheless, aerobic exercise improved 
cardiopulmonary fitness in those who successfully quit smoking. The search identified no 
trials that assessed the effects of aerobic exercise on vaping cessation. 
 
4.5.1 Design of the exercise studies and verification of smoking cessation 
Comparator groups received the same intervention as the exercise group, and consisted 
of face-to-face consultation (Abrantes et al., 2014; Hill, 1985; Kinnunen et al., 2008; 
Marcus et al., 1999; Marcus et al., 1991; Marcus et al., 1995; Marcus et al., 2005; 
Prapavessis et al., 2007; Prapavessis et al., 2016; Russell et al., 1988; Taylor et al., 1988), 
telephone counselling (Abrantes et al., 2014), behavioural treatment (Hill et al., 1993; 
Prapavessis et al., 2007), nicotine gum (Bize et al., 2010; Hill et al., 1993), nicotine patch 
(Prapavessis et al., 2007), inhalers (Bize et al., 2010), cognitive therapy (Prapavessis et al., 
2007), or combination of more than one treatment. In the trials included in the meta-
analysis, smoking cessation was confirmed by measurement of the expired CO (Abrantes 
et al., 2014; Bize et al., 2010; Hill, 1985; Hill et al., 1993; Kinnunen et al., 2008; Marcus et 
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al., 1999; Marcus et al., 1995; Marcus et al., 2005; Prapavessis et al., 2007; Prapavessis et 
al., 2016; Russell et al., 1988), saliva cotinine (Marcus et al., 1999; Marcus et al., 1991; 
Marcus et al., 1995; Marcus et al., 2005; Prapavessis et al., 2007) or plasma thiocyanate 
(Taylor et al., 1988) concentrations. 
 
4.5.2 Exercise interventions do not enhance smoking cessation 
When studying the benefits of exercise interventions for smoking cessation it is important 
to consider whether that is influenced by the frequency, intensity, time and type (FITT) of 
exercise (Brown et al., 1978; Franklin et al., 2003; Sasso et al., 2015). 
Only two high quality trials reported that aerobic exercise intervention resulted in higher 
number of long-term successful quitters compared to other interventions (Marcus et al., 
1999; Marcus et al., 1991). These trials used 3 vigorous-intensity exercise sessions a week 
for 12 – 15 weeks. This is, however, an equivocal observation as three other high quality 
trials with similar intensity, frequency and duration of exercise did not report a significant 
improvement in SC after aerobic exercise interventions (Hill, 1985; Hill et al., 1993; 
Marcus et al., 1995). As the effectiveness of exercise programs is highly dependent on 
adherence (Dishman, 1994), it is possible that the benefits of exercise in two trials 
(Marcus et al., 1999; Marcus et al., 1991) and no benefits in another trial  is related to the 
high adherence (68.7% and 88%, respectively), or low (55%) adherence (Hill et al., 1993) 
to the exercise interventions. 
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4.5.3 Exercise during smoking cessation interventions enhances VO2max and/or 
VO2peak  
Even if exercise does not benefit SC, there are substantial other benefits of exercise, such 
as the negative association with the prevalence of lung carcinoma in smokers and quitters 
(Leitzmann et al., 2009) and a significant reduction in the mortality of smokers (Siahpush 
et al., 2019). In addition, exercise during smoking cessation interventions led to a 
significant improvement in VO2max and/ or VO2peak (Abrantes et al., 2014; Hill, 1985; 
Kinnunen et al., 2008; Marcus et al., 1999; Marcus et al., 1991; Marcus et al., 1995; 
Marcus et al., 2005; Prapavessis et al., 2007). Improvements in VO2max indicate improved 
aerobic exercise capacity and may also contribute to a reduction in the development of 
numerous clinical conditions and morbidities (American College of Sports Medicine, 
2013). Besides these benefits for exercise capacity and diminishing the risk of future 
morbidity, there are also other physiological and psychological benefits to exercise as an 
adjunct to SC (Daley, 2008; Penedo and Dahn, 2005). For example, exercise led to a 
reduction in withdrawal symptoms and improvement in psychological wellbeing, such as 
reduction in anxiety, depression and mood-swings (Abrantes et al., 2014; Marcus et al., 
2005; Russell et al., 1988). Thus, even though exercise did not enhance the success rate of 




The low number of trials included in the meta-analysis on the effects of aerobic exercise 
on smoking cessation and cardiopulmonary fitness is a limitation in this review. In 
addition, this review excluded some special populations such as those suffering from 
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asthma, COPD and/or pregnant women, in which exercise may enhance the success rate 
of smoking cessation. 
4.5.5 Strengths 
This review included only randomized control trials and used a rigorous tool to assess the 
quality of the trials (CROB2) to select best quality evidence. A Meta-analysis was 
conducted for both the effects of aerobic exercise on long-term SC and VO2max and/or 
VO2peak. The review protocol was registered in PROSPERO database.  
Future research is recommended to look at the effects of aerobic exercise on vaping 
cessation. Also, better quality of trial designs is recommended for future research. There 
is some evidence that supervised exercise sessions lead to a better rate of SC. We 
therefore suggest that further trials with supervised exercise sessions are warranted to 
investigate whether indeed supervised trials enhance the success rate of SC. 
4.6 Impact/Implication 
This review suggests that aerobic exercise does not benefit the success of long-term 
smoking cessation. However, VO2max and/or VO2peak was improved in those who stopped 
smoking and will have a significant benefit for health and quality of life. It is therefore 
advisable to include aerobic exercise to any intervention for smoking cessation. 
4.7 Conclusion 
The meta-analysis showed no evidence that aerobic exercise promotes long-term 
smoking cessation.  However, aerobic exercise improved VO2max and/or VO2peak and 
mental wellbeing in those who stopped smoking.  The search identified no trials on the 
effects of aerobic exercise on vaping cessation.  
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Chapter 5 : General discussion  
This final chapter provides an overview and discussion of the results in this thesis and 
ends with some recommendations for future studies. 
The objectives of this thesis were to assess the effects of vaping and smoking on 
cardiorespiratory, vascular and muscle function and size, VO2max and low back pain. Due 
to the COVID-19 outbreak, where physiological experiments were classified as very high 
risk as per the university risk assessment due to the need to be close to the participants 
and performing aerosol-generating procedures such as spirometry and VO2max, the 
objectives had to be adjusted. The new objectives were to assess the effects of vaping 
and smoking on respiratory function (chapter 2), the effects of smoking cessation on 
respiratory and muscle function and low-grade systemic inflammation (chapter 3), and 
the effects of aerobic exercise on log-term vaping cessation and smoking cessation 
(chapter 4). Appendix 11 shows how many participants and which data was collected 
regarding the effects of vaping and smoking on cardiovascular function, muscle function 
and low back pain that had been collected before the COVID-19 outbreak and participant 
recruitment ceased. The data were insufficient for in depth analysis.  
Chapter 1 is a general introduction on what is known in the literature concerning the 
effects of vaping and smoking. Smoking is well known on its harmful effects on different 
body systems including the respiratory system, cardiovascular systems, inflammatory 
markers and blood parameters and vaping is considered a healthier alternative that may 
help in smoking cessation attempts. This chapter discusses some literature that suggests 
that vaping may not be as healthy as originally thought and hence sets the scene of the 
thesis and introduces the (revised) objectives.  
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In chapter 2, the respiratory function, respiratory muscle strength and COHb% were 
compared between vapers, cigarette smokers and non-smokers (controls). Unexpectedly, 
not only smokers, but also vapers had elevated COHb% levels. This elevated COHb% 
might cause an increased susceptibility to muscle fatigue (Morse et al., 2008). This is most 
likely not limited to leg muscles but will also affect respiratory muscles and hence may 
contribute to the reduced exercise capacity of smokers, and perhaps also vapers. 
The experiments in Chapter two showed that maximal respiratory pressures were similar 
in vapers, smokers and non-smokers. However, vaping for as little as 1.67 year caused a 
similar decrement in lung function as smoking for 4.86 years, as both vapers and smokers 
had similar FEV1, FEV1pred%, PEF, FEV1/FVC, FEF25%, FEF75%, FEF25-75%, and FEF25-75pred%, and 
both had these parameters significantly lower than non-smokers. This indicates that even 
though the vapers and smokers were asymptomatic they may show early signs of 
developing respiratory problems. This is thus in contrast to some studies reporting that 
vaping does not affect respiratory function (Polosa et al., 2017; Staudt et al., 2018; 
Vardavas et al., 2012). The cause of this discrepancy might be attributed to the duration 
of vaping/smoking, whether being a pure vaper or an ex-smoker, and/or frequency and 
volume of vaping/smoking. For example, in the current study, vapers had used e-
cigarettes daily for ≥1 year (1.67±1.00 years) with 8.30±5.23 puffs per e-cigarette, 
whereas in Polosa et al (2017); who reported no difference in FEV1 , FVC, FEV1/FVC and 
FEF25–75% between vapers and non-smokers, the duration of vaping was 8 months, in Staudt 
et al (2018); who reported no difference in FEV1 , FVC, FEV1/FVC and TLC  between vapers 
at baseline and after one week of vaping, and Vardavas et al (2012) assessed the 
immediate effects of vaping in current smokers and found no difference in FEV1 , FVC, 
FEV1/FVC after vaping. This might indicate that longer duration of vaping is needed to 
show any changes in pulmonary function.  
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Based on the findings of chapter two, the previous suggestion that vaping is a healthier, 
or safer alternative to cigarette smoking, should be treated with caution. The 
recommendation for future research includes larger sample size and should focus on 
assessing and comparing lung function in pure vapers (who have never smoked) with 
smokers. Additionally, more advanced lung function testing, such as lung diffusion 
capacity, and more sensitive airway resistance measurement (e.g. with the forced 
oscillation technique) to detect earlier changes in the pulmonary system, are desirable. It 
is also important to assess whether vaping results in less (or even none at all) low-grade 
systemic inflammation than in smokers.  
As it was found in chapter 2, that smokers have a lower respiratory function compared 
with non-smokers, it was decided to study whether these detrimental changes were 
reversible by smoking cessation. Therefore, chapter 3 describe the effects of 14 days 
smoking cessation on respiratory function, skeletal muscle function and on the blood 
parameters and inflammatory markers. Similar to other studies, the current findings  
show that MVC was similar in smokers and non-smokers (Larsson and Örlander, 1984; 
Morse et al., 2007; Wüst et al., 2008c), although others did report a lower MVC in 
smokers (Al-Obaidi et al., 2004; Barreiro et al., 2010; Örlander et al., 1979; Seymour et al., 
2010). The discrepancy between the studies may indicate that smoking per se might not 
necessarily be associated with lower MVC but may perhaps be related to exercise levels. 
In line with this, there was no significant difference in MVC between exercise level-
matched smokers and non-smokers (Larsson and Örlander, 1984; Wüst et al., 2008c). An 
interesting finding was that 14 days of smoking cessation resulted in an increase in FI in 
smokers accompanied with COHb% normalisation to levels seen in non-smokers. This 
might indicate that even as little as 3% COHb in smokers already impairs muscle fatigue 
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resistance. This is an encouraging observation, as the rapid recovery of muscle fatigue 
resistance may particularly stimulate smoking athletes to quit smoking.  
In chapter 3, it was found that total protein, albumin and glucose concentrations did not 
differ significantly between smokers and non-smokers. Additionally, it was observed that 
smoking was not associated with elevated numbers of monocytes and lymphocytes, 
something also seen by others (Malenica et al., 2017; Tulgar et al., 2016). The eosinophil 
count was, however, lower in smokers than non-smokers and remained lower after 14 
days of smoking cessation. AGEs levels remained elevated even after 14 days of smoking 
cessation. AGEs formation is sped up by smoking resulting in formation of reactive 
glycotoxins that invade the blood through lungs (Cerami et al., 1997). Additionally, the 
current study showed lower TAS and higher MDA levels in smokers that may well have 
contributed to the low-grade systemic inflammation elevated AGE levels in smokers 
(Cerami et al., 1997; Moldogazieva et al., 2019; Vlassara and Palace, 2002). Although 
neither TAS nor MDA levels changed after 14 days of smoking cessation, another study 
showed that TAS was increased and MDA reduced after 28 days of smoking cessation 
(Polidori et al., 2003). The data indicate that 14 days of smoking cessation is not long 
enough to normalise TAS, MDA and AGEs to levels seen in non-smokers. 
It was reported that cigarette smoking promotes the release of cytokines (Hasnis et al., 
2007), potentially via activation of mononuclear cells to release cytokines. Another 
possible explanation for elevated cytokine levels in smokers is the release of cytokines by 
the significantly elevated number of macrophages and neutrophils in the broncheo-
alveolar lavage fluid as seen in smoking mice (Ajime et al., 2021), over time resulting in 
low-grade systematic inflammation. 
118 | P a g e  
 
Chapter 3 also showed that smoking cessation caused IL-6, IL-10, IL-12p70, IL-4 return 
back to normal levels seen in non-smokers, while TNF-α and IL-2 were reduced after 14 
days of smoking cessation, but not yet entirely back to normal levels. The smoking 
cessation-induced reduction of toxic smoke constituents in the lungs and circulation that 
cause oxidative stress and an inflammatory response may be the main cause of the 
reduced inflammation. Whatever the cause of the reduced inflammation, it indicates the 
importance of smoking cessation to diminish systemic inflammation that might be an 
important stimulus for smokers to quit. In conclusion, it was found that smokers have 
evidence of low-grade systemic inflammation and oxidative stress, which were improved 
with 14 days smoking cessation. 
It is recommended that future research includes larger sample size and longer smoking 
cessation duration to confirm these observations and link them with cardiovascular 
function and exercise capacity. 
As chapter 3 showed that smoking cessation reversed some detrimental effects of 
smoking, it was decided to look at adding an intervention to facilitate long-term vaping 
cessation and smoking cessation. Therefore, chapter 4 describe the effects of aerobic 
exercise on long-term vaping cessation and smoking cessation. The exact mechanism by 
which aerobic exercise may help smoking cessation remain vague. However, few 
mechanisms have been suggested, including raised endorphins, distraction and increased 
self-efficacy. The literature search identified no trials on the effects of aerobic exercise on 
vaping cessation-with 13 trials included for smoking cessation. The meta-analysis results 
showed that aerobic exercise does not improve the success on long-term smoking 
cessation. However, maximal and/or peak oxygen uptake were improved in smokers who 
stopped smoking. Thus, aerobic exercise could be an add-on to other interventions, such 
as nicotine replacement therapies with nicotine patches or gum, to further enhance 
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smoking cessation rates. The results of chapter 4 indicate that even if aerobic exercise did 
not enhance the rate of long-term smoking cessation, it still should be considered as an 
intervention as the exercise enhanced fitness, and therefore may enhance general health 
and quality of life. 
Appendix 9 is the protocol for chapter 4 which was registered in PROSPERO. 
In conclusion, the work in this thesis shows that despite the general suggestion that 
vaping is a healthier alternative to smoking, vaping has similar detrimental effects to 
smoking on lung function. Therefore, the effects of vaping cessation may be similar to 
those elicited with smoking cessation, but this is as yet not investigated. It is encouraging 
that the low-grade systemic inflammation and impaired muscle function in smokers are 
readily reversible by as little as 14 days of smoking cessation. This may well stimulate 
smokers in their efforts to give up smoking. While addition of aerobic exercise to a 
smoking cessation programme does not increase the success rate of smoking cessation, it 
does improve the fitness of the abstainers. Therefore, it is advisable to include exercise in 
smoking cessation programmes, as well as measures of carboxyhaemoglobin and markers 
of inflammation.  
Limitations 
The COVID-19 pandemic led to the suspension of laboratory-based research activities and 
hence limited participant recruitment and many of the originally planned experiments. 
The following experiments were particularly affected and led to insufficient data 
collection for statistically meaningful analyses:  vascular function as assessed by brachial 
artery flow mediated dilation using ultrasound; VO2max by cardiopulmonary exercise 
testing; low back pain using the Oswestry Low Back Disability Questionnaire; 
measurements of the lower back muscles and thigh muscle size using magnetic resonance 
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imaging. In addition, the sample size of the study in chapter 2 is relatively small. Also, a 
more specific and sensitive biomarker for lipid peroxidation than MDA, such as 
Isoprostane could have been used. Longer smoking cessation programmes more than 14 
days are of interest to see whether some of the parameters that had not yet returned to 
control values would remain elevated or eventually return to values seen in non-smokers. 
Perhaps expanding the inclusion criteria in the systematic review and meta-analysis to 
include special populations such as pregnant women and those suffering from cancer, 
cardiorespiratory conditions such as asthma, COPD, may show that different populations 
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muscle function  
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Recruitment Media 190326Invitation poster- Vaping- Final 26/03/2019 2 
Information Sheet 190326Participant-Information-Sheet- Final 26/03/2019 2 
  
The Science and Engineering Research Ethics and Governance Committee favourable ethical opinion is granted with the 
following conditions  
Adherence to Manchester Metropolitan University’s Policies and procedures 
This ethical approval is conditional on adherence to Manchester Metropolitan University’s Policies, Procedures, guidance 
and Standard Operating procedures. These can be found on the Manchester Metropolitan University Research Ethics and 
Governance webpages.  
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Appendix 2: Participants Information Sheet  
 
The effects of vaping and smoking on cardiorespiratory  
and muscle function and low back pain 
 
 
This project is undertaken by Mohammad Darabseh, a PhD student at Manchester 
Metropolitan University, supervised by Prof. Hans Degens, Prof. James Selfe and 
Dr Christopher Morse. Before you decide to participate we want to explain to you 
why the research is being done and what it would involve for you. Please take time 
to read the following information carefully. Ask questions if anything you read is 
unclear or if you would like more information.   
 
What is the purpose of the study? 
Previous studies have shown that cigarette smoking has negative effects on 
cardiorespiratory, vascular and muscle function. Vaping is becoming a wide spread 
alternative and marketed as safer than cigarette smoking. There is, however, 
concern that e-cigarettes may singularly stimulate uptake of smoking, particularly 
in youth, and have an acute negative effect on cardiorespiratory health, even in 
the absence of smoking. In 2014, the potential health risk of e-cigarettes led the 
Forum of International Respiratory Societies to release a position statement that 
concluded: ‘As a precaution, electronic nicotine delivery devices should be 
restricted or banned until more information about their safety is available’. This led 
us to study the effects of vaping on cardiorespiratory, vascular and muscle function, 
and we would like also to know if vaping contributes to low back pain. 
 
Why have I been invited? 
We are inviting 105 participants, above 18 years old, cigarette smokers, vapers and 
non-smokers/vapers to participate in the study. As a participant, you should be free 
from known cardiovascular and respiratory diseases and not have had surgery in the 
last 3 months. If you have a pacemakers/metallic implants, or you are a pregnant 
women we will have to exclude you from the study as although all the procedures are 
safe, they may cause undue stress to your unborn child. 
 
Do I have to take part? 
You are free to decide whether you wish to take part or not.  If you do decide to 
take part, you will be asked to sign a consent form prior to any testing. You will be 
given a copy of this participant information sheet to keep. You are free to withdraw 
from this study at any time and without giving reasons. If you decide to withdraw 
from the study, we will also destroy, if you wish so, any documentation that 
contains personal identifiable information, but we will ask your permission to use 
the data collected up to the point of your withdrawal. You are free to withdraw from 
the study at any time. 
 
What will happen to me if I take part? 
You will be sked to attend two experimental sessions in the laboratories of the 
School of Healthcare Science at Manchester Metropolitan University. Each single 
testing session will last for around 2 hours. 
You should not consume caffeinated drinks, vape or smoke for at least 2 hours 
before the experimental session. 
First visit: 
136 | P a g e  
 
 
Height and body mass: We will record your height and weight. In addition, your 
body composition will be assessed using bioelectrical impedance, which is a 
method used to estimate body fat. 
 
A breathing (lung function) test: You will be asked to breathe through a 
mouthpiece and a noseclip will be placed to prevent you from breathing through 
your nose. After a short period of normal breathing you will be asked to inhale 
maximally followed by a forceful complete exhalation.  
To measure the strength of your respiratory muscles you will be asked to inspire or 
expire as forcefully as possible, after total expiration or inspiration respectively, 
into a portable small device with a high resistance to breathing. Next, you will be 
asked to place a probe in one of your nostrils while the other nostril is closed and 
you inspire as fast and as forceful as possible via the nose. This test will tell us 
something about your lung function and if you wish we can tell you how you 
compare to others of the same age and sex. The test will take approximately 30 
minutes. 
 
Muscle Strength and Function: For this, you sit on a strength-testing chair with 
your ankle strapped to a bar and we ask you to push against this as hard as you 
can. While you are sitting in the chair, we would like to activate your muscle by 
electrical stimulation. This gives us information about the speed of contraction and 
the susceptibility to fatigue of your muscle. It is an unusual sensation when your 
muscle contracts without you doing anything and some people find it unpleasant 
when the current is increased. However, we will get you accustomed to the 
sensations very slowly and not go any higher than you are prepared to tolerate. 
Once you are happy with the stimulation we will cause the muscle to contract at 
different frequencies and finally carry out a fatigue test in which the muscle 
contracts rhythmically for two minutes. This mimics the muscular activity involved 
in walking up stairs, but without you having to make any effort. Approximately, 40 
minutes will be allocated for this test. 
 
Completion of questionnaires: You will be asked as part of the assessment to 
complete four short questionnaires about your general physical functionality, back 
pain, quality of life, Nicotine dependence and vaping and smoking habits and 




Muscle size: The size of your lower back muscles and thigh muscle will be 
determined using Magnetic Resonance Imaging (MRI). For this, you lay in an MRI 
scanner for approximately 40 minutes. You feel nothing at all, and most people 
drift off to sleep while reclining on the couch. MRI is non-invasive technique and is 
considered to carry minimal risk. We allocate approximately one hour for both 
thigh and back muscles measurements.  
 
Vascular function test: For this test, the blood flow to the lower arm will be 
stopped for 5 min by a blood pressure cuff placed around the upper arm to a 
pressure of 240 mmHg. After 5 min the cuff will be deflated and this will cause an 
extra flow of blood through the lower arm. We will determine the flow through an 
arm artery before and after the cuff with ultrasound. You may have a transient 
tingling sensation (for a few min), but the procedure is harmless. This test will last 
for about 30 minutes. 
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Cardiorespiratory fitness: We would like you to pedal on a stationary exercise 
bike for as long as you can while the load is gradually increased. This last test will 
make you a little hot and tired but the important thing is that you stop when you 
feel you cannot continue and that you will have time to rest and recover before 
going home. During this test, you will breathe through a mouthpiece to measure 
gas exchange in the lungs and will be wearing a small device on your earlobe to 
assess oxygen saturation in the blood. Also heart rate will be monitored during the 
entire test and blood pressure will be measured before and after the test. Only 
those under 55 years will be asked to perform this test. We allocate 30 minutes for 
this test to be done.   
 
Blood Sample: We will ask to take a small blood sample by inserting a needle 
into a vein in your forearm. This only lasts a matter of seconds. This will be done a 
total of 2 times throughout the study, once before the Cardiorespiratory fitness test 
and once after, to allow us to look for biological changes that may occur in our 
response to the exercise. 
 
Expenses and payments? 
Travel expenses can be reimbursed and you will receive a £10 voucher upon 
completion of all experiments as a token of our appreciation. 
 
What are the possible disadvantages and risks of taking part? 
 
Electrical stimulation: Some people may find electrical stimulation unpleasant. 
However, you will be introduced to electrical stimulation by gradual increase of the 
stimulation intensity in order to avoid any unpleasant feeling. Also, the stimulation 
will not be increased if it led to intolerable muscle contraction.  
  
Cycle ergometer test: Some people experience abnormal changes to blood 
pressure, fainting, angina, and in rare instances heart attack or stroke. This is, 
however, unlikely, and you must inform us if you suffer from any cardiovascular or 
respiratory problems. To further minimise any risk to you we will keep a close eye 
on you throughout the test. 
 
A breathing (lung function) test: Some participants might feel slightly tired after 
doing the breathing test. However, you will have opportunity to recover your breath 
between components of the test. 
 
Vascular function test, Ultrasound and MRI: Are unlikely to have any pain or 
adverse events.  
 
What are the possible benefits of taking part? 
By participating in this study, you will help us in understanding the effects of 
vaping on cardiorespiratory, vascular and muscle function. This knowledge will 
inform health services and policy makers to design new policies on vaping. You 
are going to get some information on your fitness level and pulmonary function. 
 
Will my taking part in the study be kept confidential? 
All personal information collected about you will be treated as confidential and 
privileged, and we will only collect information about you that we need to answer 
the questions of our research. We would like to reassure you that your personal 
information will be kept strictly confidential, and will only be accessible to members 
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of the research team involved in the collection and processing / analysis of that 
data. No personal identifying information will appear in our published results.   
 
Involvement of the General Practitioner/Family Doctor (GP) 
The assessment tests will be conducted in the study would not affect your health, 
therefore, contacting your GP is not necessary.    
 
What will happen to the results of the research study? 
The information and data will be used for scientific presentations and publications 
in such a way that they can not be linked back to you. 
 
Who is organising or sponsoring the research? 
This research is not being funded externally and is the PhD work of Mohammad 
Darabseh, organised and overseen by Manchester Metropolitan University. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you may wish to speak to the 
researchers who will do their best to answer your questions. You should contact 
Mohammad Darabseh in the first instance, or, alternatively, you may want to 
contact the project lead supervisor, Prof. Hans Degens (see contact details at the 
end of this page).  
 
Mohammad Darabseh (PhD student) 
Mohammad.z.darabseh@stu.mmu.ac.uk  
School of Healthcare Science 
Manchester Metropolitan University  
Manchester  




Professor Hans Degens (project lead supervisor) 
Full professor 
School of Healthcare Science 
H.degens@mmu.ac.uk  
School of Healthcare Science 
Manchester Metropolitan University  
Manchester  
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Appendix 3: Recruitment poster  
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Appendix 4: Consent form  
Date 
Name 
School of Healthcare Science 




Title of Project: Impact of vaping and smoking on cardiorespiratory and muscle 
function and low back pain. 
 
Name of Researcher: Mohammad Darabseh, Prof Hans Degens, Prof James Selfe, 
Dr. Liam Bagley, Dr Chris Morse  
 
Participant Identification Code for this project: 
                 Please 
initial box 
1. I confirm that I have read and understood the information sheet  
dated 23 November, 2019 for the above project and have had the  
opportunity to ask questions about all procedures. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason to the named researcher. 
 
3. I give permission for my answers and information to be archived  
as part of this research project, making it available to future research. 
 
4. I understand that my data will be anonymised. 
 




________________________ ________________         ____________________ 
Name of Participant Date Signature 
 
_________________________ ________________         ____________________ 




To be signed and dated in presence of the participant 
 
Once this has been signed, you will receive a copy of your signed and dated consent form 
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Date of Birth: __________________   Age: __________Gender: 
____________________ 
 
Please answer the following questions by putting a circle round the appropriate response or 
filling in the blank. 
 
  1. How would you describe your present level of activity? 
 Sedentary / Moderately active / Active / Highly active 
 
  2. How would you describe you present level of fitness? 
 Unfit / Moderately fit / Trained / Highly trained 
 
  3. How would you consider your present body weight? 
 Underweight / Ideal / Slightly over / Very overweight 
 
  4. Smoking Habits Are you currently a smoker?    Yes / No 
    If yes, how many do you smoke   ……..  
per day 
    Are you a previous smoker?    Yes / No 
    If yes, how long is it since you stopped?  .........  
years 
 
  5. Do you drink alcohol?       Yes / No 
 If you answered Yes, do you usually have? 
 An occasional drink / a drink every day / more than one drink a day? 
 
  6.    Have you had to consult your doctor within the last 6 months?   Yes / No 





  7. Are you presently taking any form of medication?   Yes / No 






Physical Activity Readiness Questionnaire 
(PAR-Q) 
Manchester Metropolitan University 
Department of Sport and Exercise Science 
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8. As far as you are aware, do you suffer or have you ever suffered from: 
a Diabetes?       Yes / No b Asthma?       Yes / No 
 c Epilepsy?       Yes / No d Bronchitis?        Yes / No 
e *Any form of heart complaint? Yes / No f Raynaud’s Disease?      Yes / No 
 g *Marfan’s Syndrome?     Yes / No h *Aneurysm/embolism?  Yes / No 
 I   Anaemia       Yes / No  
  
Any other medical condition or illness?                Yes / No 





9. *Is there a history of heart disease in your family?   Yes / No 
 
10. *Do you currently have any form of muscle or joint injury?       Yes / No  







11. Have you suspended your normal training in the last 2 weeks?   Yes / No 







If blood is not being taken from you please disregard Section 12 below. 
 
12. *Please read the following questions: 
a)  Are you suffering from any known serious infection?  Yes / No 
b) Have you had jaundice within the previous year?   Yes / No 
c) Have you ever had any form of hepatitis?    Yes / No 
d) Are you living with HIV?      Yes / No 
e) Have you had unprotected sexual intercourse with any 
person from an HIV high-risk population?    Yes / No 
f) Have you ever been involved in intravenous drug use?  Yes / No 
g) Are you hemophiliac?       Yes / No 
 
13. Have you participated in any form of exercise testing before?  Yes / No 
If the answer is Yes, have you ever needed to terminate a test prior to completion, 
for health and safety reasons?       
 Yes / No  









14. As far as you are aware, is there anything that might prevent you from 







IF THE ANSWER TO ANY OF THE ABOVE IS YES THEN: 
a) Discuss the nature of the problem with the Principal 
Investigator.  
b) Questions indicated by  * please provide consent from your 
GP.      
 
 
As far as I am aware the information I have given is accurate. 
 
Participant’s Signature:  ……………………………………………………………... 
 
Supervisor’s Signature:  ……………………………………………………………... 
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Appendix 6: QUESTIONNAIRE ON SMOKING AND VAPING 
HABITS 







1) Do you smoke at present? Vape / Yes / No  
If no please continue to question 2 
If yes please continue to question 3 
If you Vape continue to question 12 
2) Have you smoked before? Yes / No 
If no, thank you for your co-operation 
If yes please continue to question 3 
3) At what age did you start smoking?  
____________________ 




5) What kind of tobacco do you normally 
smoke?   
Light / Mild / Heavy 
6) Do/did you normally inhale? Yes / No 
7) Do you use a filter or non-filter cigarettes? Filter / No Filter 
If no filter, please answer questions 10 & 11 also 
8) How many cigarettes a day did you smoke 
when you started smoking? 
 
____________________ 




10)  How much tobacco a day did you use 
when you started smoking? 
 
____________________ 




12)  What is the system/style of vaping do Mouth to Lung    (MTL) 
INSTRUCTIONS- This set of questions asks for your smoking and vaping habits. Answer every question 
by marking the answer as indicated. If you are unsure about how to answer a question, please give 
the best answer you can. 
 
INSTRUCTIONS- This set of questions asks for your smoking and vaping habits. Answer every question 
by marking the answer as indicated. If you are unsure about how to answer a question, please give 
the best answer you can. 
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you use?            Direct to Lung     (DL) 
13)  What is the battery voltage that you 
usually vape at? 
 
____________________ 
14)  At what age did you start vaping?  
____________________ 




16)  What kind of e-liquid/juice do you 
normally vape?   
70 PG / 30 VG 
          50 G / 50 VG 
          70 G / 30 PG 
          80 G / 20 PG 
            Max VG 
            Other ____________________ 
17)  How much e-liquid / juice are you 
consuming per day? 
 
____________________ml/day 
18)  How many e-liquid cartridges do you 
consume per week? 
 
____________________/week 
19)  Do you vape e-liquid / juice that contains 
nicotine? 
Yes / No 
20)  What is the cartridge e-liquid/juice 
nicotine concentration (strength)? 
 
____________________mg/ml 
21)  What is the flavour of the e-liquid/juice 








23)  What is the approximate interval (time) 
between puffs of single use? 
 
____________________ 
24)  Did you smoke cigarettes /cigar/ pipe 
before staring vaping? 
Yes / No 
If yes, please write for how long 
____________________ 
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25)  Did vaping act as a way of encouraging 
you to take up smoking? 
Yes / No 
 
26)  Are you vaping as a way to reduce your 
cigarette smoking? 
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Appendix 9: Systematic review and meta-analysis protocol 
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Appendix 11: Insufficient data collected before COVID-19 
outbreak  
As the objectives of this thesis were to assess and compare the effects of vaping and 
smoking on: respiratory function, vascular function and VO2max, muscle function, size and 
low back pain and due to the outbreak of the COVID-19 pandemic, the objectives had to 
be adjusted as mentioned in the general discussion. The below table (A) and figures (A1, 
A2 and A3) show how many participants, and which data were collected regarding the 
effects of vaping and smoking on cardiovascular function, muscle function, size and low 
back pain that had been collected before the COVID-19 outbreak and participant 
recruitment ceased during the pandemic. The data were insufficient for in depth analysis. 
 The vascular function was meant to be assessed by brachial artery flow mediated dilation 
using ultrasound, VO2max by cardiopulmonary exercise testing, low back pain using 
Oswestry Low Back Disability Questionnaire subjectively and objectively by measuring the 
lower back muscles size, and thigh muscle size using magnetic resonance imaging, muscle 













(2) (3) (5) (2) (4) (3) 
FMD (3) (3) (4) (3) (6) (4) 
(X): number of participants; MRI: Magnetic Resonance Imaging; ODI: Oswestry 
Low Back Disability Questionnaire; FMD: Flow Mediated Dilation. 
Table A: number of participants recruited before the pandemic. 
 
Table A: number of participants recruited before the pandemic. 
















Figure A1: An example about data collected before the pandemic using the brachial artery 
flow mediated dilation technique for one participant. 
 
Figure A1: An example about data collected before the pandemic using the brachial artery 




















Figure A2: an example of lower back muscles (upper figure) and thigh muscles (lower 
figure) as scanned in MRI in one participant before the pandemic. 
 
Figure A2: an example of lower back muscles (upper figure) and thigh muscles (lower 
figure) as scanned in MRI in one participant before the pandemic. 













Figure A3: VO2max: Maximal oxygen uptake in: Non-smokers (M:6; W:4), smokers (M:4; 
W:3) and vapers (M:3; W:3). 
 
Figure A3: VO2max: Maximal oxygen uptake in: Non-smokers (M:6; W:4), smokers (M:4; 
W:3) and vapers (M:3; W:3). 
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